https://oncomarks.com/index.php 2026-07-28 daily 1.0 https://oncomarks.com/Trials_Submitted.php 2026-07-28 daily 0.9 https://oncomarks.com/About.php 2026-07-28 monthly 0.5 https://oncomarks.com/Trial_View.php?Study_ID=793&slug=impact-of-number-of-bone-metastases-on-cancer-control-outcomes-in-mhspc-independent-of-the-axial-skeleton-chaarted-defin 2026-07-24 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=792&slug=metastasis-directed-therapy-and-standard-of-care-versus-standard-of-care-for-oligometastatic-prostate-cancer-wolverine-a 2026-07-24 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=791&slug=temozolomide-versus-radiotherapy-as-first-line-therapy-for-low-grade-glioma-mature-results-of-a-randomized-phase-iii-tri 2026-07-23 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=790&slug=survival-analysis-of-the-wsg-tp-ii-trial-neoadjuvant-trastuzumab-and-pertuzumab-plus-endocrine-therapy-versus-chemothera 2026-07-23 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=789&slug=durvalumab-with-radiation-therapy-in-patients-with-inoperable-locally-advanced-non-small-cell-lung-cancer-ineligible-for 2026-07-23 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=788&slug=enfortumab-vedotin-and-pembrolizumab-in-cisplatin-eligible-bladder-cancer 2026-07-23 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=786&slug=adjuvant-atezolizumab-versus-observation-in-muscle-invasive-urothelial-carcinoma-imvigor010-a-multicentre-open-label-ran 2026-07-21 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=787&slug=updated-overall-survival-by-circulating-tumor-dna-status-from-the-phase-3-imvigor010-trial-adjuvant-atezolizumab-versus- 2026-07-21 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=785&slug=metronomic-capecitabine-plus-aromatase-inhibitor-as-initial-therapy-in-patients-with-hormone-receptor-positive-human-epi 2026-07-21 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=784&slug=final-results-from-the-atalante-engot-ov29-randomized-phase-iii-trial-of-atezolizumab-bevacizumab-and-platinum-based-the 2026-07-20 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=783&slug=adjuvant-chemotherapy-6-chemoradiotherapy-for-adenocarcinoma-of-the-pancreatic-head-results-of-the-radiotherapy-random-a 2026-07-20 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=781&slug=abiraterone-or-enzalutamide-for-patients-with-metastatic-castration-sensitive-prostate-cancer-a-nationwide-veterans-affa 2026-07-17 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=780&slug=consolidative-thoracic-radiotherapy-with-atezolizumab-maintenance-in-extensive-stage-small-cell-lung-cancer-the-phase-2- 2026-07-14 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=779&slug=ensartinib-in-resected-alk-positive-non-small-cell-lung-cancer 2026-07-09 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=778&slug=ensartinib-vs-crizotinib-for-patients-with-anaplastic-lymphoma-kinase-positive-non-small-cell-lung-cancer-a-randomized-c 2026-07-09 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=777&slug=addition-of-metastasis-directed-therapy-to-systemic-therapy-for-oligometastatic-pancreatic-ductal-adenocarcinoma-extend- 2026-07-04 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=776&slug=systemic-therapy-with-or-without-local-intervention-for-oligometastatic-oesophageal-squamous-cell-carcinoma-eso-shanghai 2026-07-04 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=775&slug=addition-of-metastasis-directed-therapy-to-standard-of-care-for-oligometastatic-disease-primary-aggregated-analysis-of-a 2026-07-04 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=774&slug=continuous-androgen-deprivation-therapy-with-or-without-metastasis-directed-therapy-for-oligometastatic-prostate-cancer- 2026-07-04 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=772&slug=randomized-trial-of-first-line-tyrosine-kinase-inhibitor-with-or-without-radiotherapy-for-synchronous-oligometastatic-eg 2026-07-04 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=773&slug=egfr-tkis-plus-stereotactic-body-radiation-therapy-sbrt-for-stage-iv-non-small-cell-lung-cancer-nsclc-a-prospective-mult 2026-07-04 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=769&slug=comparison-of-immediate-vs-deferred-cytoreductive-nephrectomy-in-patients-with-synchronous-metastatic-renal-cell-carcino 2026-07-02 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=770&slug=sunitinib-alone-or-after-nephrectomy-in-metastatic-renal-cell-carcinoma 2026-07-02 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=768&slug=stereotactic-radiation-for-systemic-therapy-naive-oligometastatic-kidney-cancer-final-results-of-a-phase-2b-trial 2026-07-02 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=767&slug=adjuvant-everolimus-in-patients-with-completely-resected-very-high-risk-renal-cell-carcinoma-of-clear-cell-histology-res 2026-07-02 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=766&slug=adjuvant-nivolumab-vs-observation-in-resected-non-small-cell-lung-cancer-a-randomized-clinical-trial 2026-07-02 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=763&slug=lenvatinib-everolimus-and-the-combination-in-patients-with-metastatic-renal-cell-carcinoma-a-randomised-phase-2-open-lab 2026-07-02 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=764&slug=phase-3-trial-of-everolimus-for-metastatic-renal-cell-carcinoma 2026-07-02 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=765&slug=cabozantinib-versus-everolimus-in-advanced-renal-cell-carcinoma-meteor-final-results-from-a-randomised-open-label-phase- 2026-07-02 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=760&slug=lenvatinib-plus-pembrolizumab-versus-sunitinib-in-first-line-treatment-of-advanced-renal-cell-carcinoma-final-prespecifi 2026-07-02 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=761&slug=nivolumab-plus-ipilimumab-versus-sunitinib-for-first-line-treatment-of-advanced-renal-cell-carcinoma-extended-8-year-fol 2026-07-02 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=762&slug=pembrolizumab-plus-axitinib-versus-sunitinib-for-advanced-clear-cell-renal-cell-carcinoma-5-year-survival-and-biomarker- 2026-07-02 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=759&slug=a-multicenter-randomized-phase-ii-trial-of-lenvatinib-plus-everolimus-versus-cabozantinib-in-patients-with-metastatic-cl 2026-07-02 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=758&slug=caboseq-3-comparison-of-cabozantinib-versus-sunitinib-following-first-line-nivolumab-ipilimumab-for-metastatic-renal-cel 2026-07-02 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=757&slug=5-year-outcomes-after-stereotactic-ablative-body-radiotherapy-for-primary-renal-cell-carcinoma-an-individual-patient-dat 2026-07-02 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=756&slug=stereotactic-ablative-body-radiotherapy-for-primary-kidney-cancer-trog-15-03-fastrack-ii-a-non-randomised-phase-2-trial 2026-07-02 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=754&slug=adjuvant-sunitinib-in-high-risk-renal-cell-carcinoma-after-nephrectomy 2026-07-02 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=755&slug=adjuvant-sunitinib-for-high-risk-renal-cell-carcinoma-after-nephrectomy-subgroup-analyses-and-updated-overall-survival-r 2026-07-02 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=753&slug=adjuvant-everolimus-after-surgery-for-renal-cell-carcinoma-everest-a-double-blind-placebo-controlled-randomised-phase-3- 2026-07-02 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=752&slug=adjuvant-pazopanib-versus-placebo-after-nephrectomy-in-patients-with-localized-or-locally-advanced-renal-cell-carcinoma- 2026-07-02 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=751&slug=adjuvant-atezolizumab-versus-placebo-for-patients-with-renal-cell-carcinoma-at-increased-risk-of-recurrence-following-re 2026-07-02 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=750&slug=perioperative-nivolumab-versus-observation-in-patients-with-renal-cell-carcinoma-undergoing-nephrectomy-prosper-ecog-acr 2026-07-02 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=749&slug=adjuvant-nivolumab-plus-ipilimumab-versus-placebo-for-localised-renal-cell-carcinoma-after-nephrectomy-checkmate-914-a-d 2026-07-02 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=748&slug=adjuvant-nivolumab-for-localized-renal-cell-carcinoma-at-high-risk-of-recurrence-after-nephrectomy-part-b-of-the-randomi 2026-07-02 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=747&slug=overall-survival-with-adjuvant-pembrolizumab-in-renal-cell-carcinoma 2026-07-02 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=746&slug=adjuvant-pembrolizumab-plus-belzutifan-for-renal-cell-carcinoma 2026-07-02 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=745&slug=efficacy-and-safety-of-intraoperative-hyperthermic-intraperitoneal-chemotherapy-for-locally-advanced-colon-cancer-a-phas 2026-07-02 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=744&slug=reirradiation-for-recurrent-head-and-neck-squamous-cell-carcinoma-international-expert-consensus-recommendations-endorse 2026-07-02 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=743&slug=single-agent-bevacizumab-or-lomustine-versus-a-combination-of-bevacizumab-plus-lomustine-in-patients-with-recurrent-glio 2026-07-01 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=740&slug=perioperative-systemic-therapy-versus-surgery-alone-for-resectable-colorectal-peritoneal-only-metastases-cairo6-a-random 2026-07-01 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=739&slug=sbrt-plus-abiraterone-acetate-and-adt-versus-abiraterone-acetate-and-adt-in-oligometastatic-castrate-resistant-prostate- 2026-07-01 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=738&slug=internal-mammary-chain-and-medial-supraclavicular-lymph-node-irradiation-in-stage-i-iii-breast-cancer-eortc-trial-22922- 2026-07-01 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=737&slug=dose-escalation-with-intraoperative-radiotherapy-in-newly-diagnosed-glioblastoma-intrago-ii-an-open-label-multicentre-ra 2026-07-01 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=736&slug=effect-of-68ga-ga-psma-11-pet-ct-in-the-diagnosis-of-prostate-cancer-in-men-with-equivocal-or-clinically-high-risk-non-s 2026-07-01 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=735&slug=tailoring-radiotherapy-in-ct1-2n1-breast-cancer-to-nodal-response-on-primary-chemotherapy-rapchem-boog-2010-03-10-year-f 2026-07-01 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=734&slug=targeting-homologous-recombination-deficiency-with-intensified-chemotherapy-versus-standard-chemotherapy-followed-by-ola 2026-07-01 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=733&slug=aumolertinib-with-or-without-chemotherapy-in-egfr-mutated-advanced-non-small-cell-lung-cancer-aeneas2-an-open-label-mult 2026-07-01 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=732&slug=anti-egfr-based-maintenance-versus-stop-and-go-in-patients-with-left-sided-non-msi-h-ras-braf-wt-metastatic-colorectal-c 2026-06-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=731&slug=adjusted-comparison-of-first-line-enfortumab-vedotin-plus-pembrolizumab-versus-platinum-based-chemotherapy-avelumab-main 2026-06-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=730&slug=survival-outcomes-in-breast-cancer-patients-with-use-of-vaginal-estrogen-therapy-a-seer-analysis 2026-06-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=729&slug=single-fraction-stereotactic-body-radiotherapy-for-localized-prostate-cancer-a-nonrandomized-clinical-trial 2026-06-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=728&slug=becotatug-vedotin-for-recurrent-metastatic-nasopharyngeal-carcinoma-magic-m001-a-multicenter-randomized-trial 2026-06-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=727&slug=saci-io-hr-a-randomized-phase-ii-trial-of-sacituzumab-govitecan-with-or-without-pembrolizumab-in-patients-with-metastati 2026-06-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=726&slug=camizestrant-a-next-generation-oral-serd-versus-fulvestrant-in-post-menopausal-women-with-oestrogen-receptor-positive-he 2026-06-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=725&slug=dose-escalated-simultaneous-integrated-boost-radiotherapy-in-early-breast-cancer-import-high-a-multicentre-phase-3-non-i 2026-06-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=724&slug=long-term-efficacy-and-safety-of-lorlatinib-versus-alectinib-in-anaplastic-lymphoma-kinase-positive-advanced-metastatic- 2026-06-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=722&slug=adding-ovarian-suppression-to-tamoxifen-for-premenopausal-women-with-hormone-receptor-positive-breast-cancer-after-chemo 2026-06-28 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=721&slug=risk-of-breast-cancer-after-ovarian-cancer-in-women-with-a-pathogenic-likely-pathogenic-variant-in-brca1-or-brca2 2026-06-28 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=720&slug=maintenance-pemetrexed-pembrolizumab-versus-pembrolizumab-in-non-small-cell-lung-cancer-a-propensity-score-weighted-anal 2026-06-28 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=719&slug=concurrent-versus-sequential-radiation-dose-escalation-to-the-surgical-cavity-for-conservative-treatment-of-high-risk-ea 2026-06-28 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=718&slug=atezolizumab-with-bevacizumab-and-nonplatinum-chemotherapy-for-recurrent-ovarian-cancer-final-results-from-the-placebo-c 2026-06-28 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=717&slug=benefit-of-chemoradiotherapy-versus-chemotherapy-after-induction-therapy-for-conversion-of-unresectable-into-resectable- 2026-06-28 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=716&slug=radiation-vs-trans-oral-surgery-for-treatment-de-escalation-in-hpv-related-oropharyngeal-cancers-primary-analysis-of-the 2026-06-28 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=715&slug=effect-of-axillary-dissection-vs-no-axillary-dissection-on-10-year-overall-survival-among-women-with-invasive-breast-can 2026-06-27 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=714&slug=androgen-deprivation-and-radiotherapy-with-or-without-docetaxel-for-localized-high-risk-prostate-cancer-long-term-follow 2026-06-27 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=713&slug=long-term-follow-up-of-jcog1008-a-randomized-phase-ii-iii-trial-of-chemoradiotherapy-comparing-3-weekly-cisplatin-with-w 2026-06-27 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=712&slug=prediction-of-anthracycline-benefit-in-hormone-receptor-positive-human-epidermal-growth-factor-receptor-2-negative-early 2026-06-27 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=711&slug=overall-survival-of-patients-with-localized-soft-tissue-sarcoma-treated-with-or-without-adjuvant-chemotherapy-deepsarc-a 2026-06-27 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=710&slug=sequential-alternation-of-nal-iri-5-fu-and-gemcitabine-nab-paclitaxel-versus-nal-iri-5-fu-versus-gemcitabine-nab-paclita 2026-06-27 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=709&slug=ramucirumab-plus-docetaxel-versus-placebo-plus-docetaxel-for-second-line-treatment-of-stage-iv-non-small-cell-lung-cance 2026-06-27 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=707&slug=five-year-survival-outcomes-from-the-pacific-trial-durvalumab-after-chemoradiotherapy-in-stage-iii-non-small-cell-lung-c 2026-06-27 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=708&slug=simultaneous-durvalumab-and-platinum-based-chemoradiotherapy-in-unresectable-stage-iii-non-small-cell-lung-cancer-the-ph 2026-06-27 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=706&slug=lorlatinib-versus-crizotinib-as-first-line-treatment-for-advanced-alk-positive-non-small-cell-lung-cancer-7-year-update- 2026-06-27 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=705&slug=first-line-lorlatinib-or-crizotinib-in-advanced-alk-positive-lung-cancer 2026-06-27 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=702&slug=osimertinib-in-resected-egfr-mutated-non-small-cell-lung-cancer 2026-06-27 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=699&slug=toripalimab-plus-chemotherapy-for-first-line-treatment-of-advanced-non-small-cell-lung-cancer-choice-01-final-os-and-bio 2026-06-27 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=698&slug=patient-reported-outcomes-in-castration-resistant-prostate-cancer-with-bone-metastases-treated-with-radium-223-with-or-w 2026-06-27 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=697&slug=phase-iii-randomized-placebo-controlled-trial-on-repurposing-olanzapine-for-prevention-of-radiotherapy-induced-nausea-an 2026-06-26 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=696&slug=dose-intensified-versus-conventional-dose-salvage-radiotherapy-for-biochemically-recurrent-prostate-cancer-after-prostat 2026-06-24 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=694&slug=omitting-axillary-dissection-in-breast-cancer-with-sentinel-node-metastases 2026-06-23 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=693&slug=radiotherapy-versus-transoral-robotic-surgery-for-oropharyngeal-squamous-cell-carcinoma-final-results-of-the-orator-rand 2026-06-23 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=692&slug=randomized-phase-ii-trial-of-immunotherapy-based-total-neoadjuvant-therapy-for-proficient-mismatch-repair-or-microsatell 2026-06-23 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=691&slug=cosmetic-results-and-side-effects-of-accelerated-partial-breast-irradiation-versus-whole-breast-irradiation-for-low-risk 2026-06-23 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=690&slug=pembrolizumab-plus-chemotherapy-versus-chemotherapy-for-advanced-esophageal-cancer-5-year-extended-follow-up-for-the-ran 2026-06-23 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=689&slug=long-term-health-outcomes-of-bilateral-salpingo-oophorectomy-in-brca1-and-brca2-pathogenic-variant-carriers-with-persona 2026-06-22 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=688&slug=survival-outcomes-with-or-without-risk-reducing-mastectomy-in-brca1-and-brca2-pathogenic-variant-carriers 2026-06-22 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=687&slug=bacillus-calmette-guerin-plus-mitomycin-versus-bacillus-calmette-guerin-alone-for-bacillus-calmette-guerin-naive-non-mus 2026-06-22 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=686&slug=metastases-directed-therapy-in-addition-to-standard-systemic-therapy-in-oligometastatic-castration-resistant-prostate-ca 2026-06-22 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=685&slug=switch-to-fulvestrant-and-palbociclib-versus-no-switch-in-advanced-breast-cancer-with-rising-esr1-mutation-during-aromat 2026-06-22 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=681&slug=dostarlimab-and-niraparib-in-primary-advanced-ovarian-cancer 2026-06-21 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=682&slug=atezolizumab-bevacizumab-and-chemotherapy-for-newly-diagnosed-stage-iii-or-iv-ovarian-cancer-placebo-controlled-randomiz 2026-06-21 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=683&slug=durvalumab-with-carboplatin-paclitaxel-and-bevacizumab-followed-by-durvalumab-and-bevacizumab-with-or-without-olaparib-m 2026-06-21 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=684&slug=overall-survival-and-patient-reported-outcome-results-from-the-placebo-controlled-randomized-phase-iii-imagyn050-gog-301 2026-06-21 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=677&slug=phase-iii-randomized-trial-of-docetaxel-carboplatin-versus-paclitaxel-carboplatin-as-first-line-chemotherapy-for-ovarian 2026-06-21 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=678&slug=a-multicenter-randomized-trial-of-flat-dosing-versus-intrapatient-dose-escalation-of-single-agent-carboplatin-as-first-l 2026-06-21 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=679&slug=a-randomized-trial-of-lymphadenectomy-in-patients-with-advanced-ovarian-neoplasms 2026-06-21 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=680&slug=randomized-trial-of-primary-debulking-surgery-versus-neoadjuvant-chemotherapy-for-advanced-epithelial-ovarian-cancer-sco 2026-06-21 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=675&slug=randomized-phase-iii-trial-of-three-versus-six-cycles-of-adjuvant-carboplatin-and-paclitaxel-in-early-stage-epithelial-o 2026-06-21 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=676&slug=is-there-a-high-risk-subgroup-of-stage-i-epithelial-ovarian-cancer-that-is-most-likely-to-benefit-from-6-versus-3-cycles 2026-06-21 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=674&slug=pembrolizumab-versus-chemotherapy-for-microsatellite-instability-high-or-mismatch-repair-deficient-metastatic-colorectal 2026-06-21 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=673&slug=neoadjuvant-chemoradiotherapy-versus-neoadjuvant-chemotherapy-for-initially-unresectable-locally-advanced-colon-cancer-s 2026-06-21 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=672&slug=neoadjuvant-immunotherapy-in-locally-advanced-mismatch-repair-deficient-colon-cancer 2026-06-21 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=671&slug=preoperative-chemotherapy-for-operable-colon-cancer-mature-results-of-an-international-randomized-controlled-trial 2026-06-21 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=670&slug=alliance-a221805-duloxetine-to-prevent-oxaliplatin-induced-chemotherapy-induced-peripheral-neuropathy-a-randomized-doubl 2026-06-21 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=668&slug=lack-of-survival-benefit-of-pelvic-lymph-node-dissection-for-patients-with-radical-prostatectomy-and-postprostatectomy-r 2026-06-20 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=667&slug=pelvic-lymph-node-dissection-in-prostate-cancer-update-from-a-randomized-clinical-trial-of-limited-versus-extended-disse 2026-06-20 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=666&slug=comparison-of-extended-and-standard-lymph-node-dissection-in-radical-cystectomy-for-urothelial-bladder-cancer-a-systemat 2026-06-20 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=664&slug=the-efficacy-and-safety-of-mirvetuximab-soravtansine-in-fr-positive-third-line-and-later-recurrent-platinum-sensitive-ov 2026-06-20 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=663&slug=olaparib-versus-nonplatinum-chemotherapy-in-patients-with-platinum-sensitive-relapsed-ovarian-cancer-and-a-germline-brca 2026-06-20 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=662&slug=mirvetuximab-soravtansine-in-fr-positive-platinum-resistant-ovarian-cancer 2026-06-20 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=661&slug=integrating-metronomic-therapy-with-standard-chemotherapy-in-advanced-unresectable-head-and-neck-cancer-a-randomized-tri 2026-06-20 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=660&slug=adjuvant-leuprorelin-acetate-after-radical-prostatectomy-in-men-with-high-risk-localized-prostate-cancer-results-of-the- 2026-06-20 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=659&slug=perioperative-serplulimab-with-neoadjuvant-chemotherapy-versus-perioperative-chemotherapy-in-pd-l1-positive-gastric-canc 2026-06-20 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=658&slug=atezolizumab-and-chemotherapy-for-advanced-or-recurrent-endometrial-cancer-attend-a-randomised-double-blind-placebo-cont 2026-06-20 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=655&slug=efficacy-and-safety-of-12-weekly-versus-4-weekly-zoledronic-acid-for-prolonged-treatment-of-patients-with-bone-metastase 2026-06-20 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=654&slug=elective-nodal-radiation-therapy-in-localized-prostate-cancer-a-meta-analysis 2026-06-19 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=653&slug=clinical-outcomes-of-external-radiotherapy-boost-versus-no-boost-to-radiologically-positive-lymph-nodes-in-figo-stage-ii 2026-06-19 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=652&slug=short-course-based-tnt-with-or-without-pd-1-inhibitor-for-pmmr-locally-advanced-rectal-cancer-phase-2-results-of-a-rando 2026-06-19 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=651&slug=therapeutic-value-of-sentinel-lymph-node-biopsy-in-patients-with-melanoma-a-randomized-clinical-trial 2026-06-19 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=650&slug=combination-of-encorafenib-and-binimetinib-followed-by-ipilimumab-and-nivolumab-versus-ipilimumab-and-nivolumab-in-patie 2026-06-19 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=649&slug=timing-of-durvalumab-consolidation-and-survival-in-non-small-cell-lung-cancer-a-population-based-analysis 2026-06-19 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=648&slug=adjuvant-hyperthermic-intraperitoneal-chemotherapy-in-patients-with-locally-advanced-colon-cancer-colopec-5-year-results 2026-06-19 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=647&slug=impact-of-lead-in-adt-on-grade-3-neutropenia-in-patients-with-metastatic-hormone-sensitive-prostate-cancer-treated-with- 2026-06-19 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=646&slug=neoadjuvant-ctla-4-pd-l-1-blockade-versus-surgery-1-2-chemotherapy-in-deficient-mismatch-repair-microsatellite-instabili 2026-06-19 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=644&slug=first-line-immunotherapy-with-or-without-chemotherapy-versus-braf-plus-mek-inhibitors-in-brafv600e-mutated-metastatic-no 2026-06-19 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=645&slug=comparable-effectiveness-of-weight-based-and-fixed-dose-pembrolizumab-in-non-small-cell-lung-cancer-insights-from-a-nati 2026-06-19 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=643&slug=intermittent-versus-continuous-androgen-deprivation-in-prostate-cancer 2026-06-19 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=642&slug=prophylactic-radiation-therapy-versus-standard-of-care-for-patients-with-high-risk-asymptomatic-bone-metastases-a-multic 2026-06-19 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=641&slug=overall-survival-results-from-the-polo-trial-a-phase-iii-study-of-active-maintenance-olaparib-versus-placebo-for-germlin 2026-06-19 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=640&slug=adjuvant-hyperthermic-intraperitoneal-chemotherapy-in-patients-with-locally-advanced-colon-cancer-colopec-a-multicentre- 2026-06-19 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=639&slug=cytoreductive-surgery-plus-hyperthermic-intraperitoneal-chemotherapy-versus-cytoreductive-surgery-alone-for-colorectal-p 2026-06-19 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=638&slug=primary-chemotherapy-versus-primary-surgery-for-newly-diagnosed-advanced-ovarian-cancer-chorus-an-open-label-randomised- 2026-06-19 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=637&slug=niraparib-maintenance-therapy-in-platinum-sensitive-recurrent-ovarian-cancer 2026-06-19 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=636&slug=olaparib-tablets-as-maintenance-therapy-in-patients-with-platinum-sensitive-relapsed-ovarian-cancer-and-a-brca1-2-mutati 2026-06-19 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=635&slug=bevacizumab-combined-with-chemotherapy-for-platinum-resistant-recurrent-ovarian-cancer-the-aurelia-open-label-randomized 2026-06-19 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=634&slug=a-phase-3-trial-of-bevacizumab-in-ovarian-cancer 2026-06-19 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=633&slug=incorporation-of-bevacizumab-in-the-primary-treatment-of-ovarian-cancer 2026-06-19 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=632&slug=weekly-dose-dense-chemotherapy-in-first-line-epithelial-ovarian-fallopian-tube-or-primary-peritoneal-carcinoma-treatment 2026-06-19 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=631&slug=phase-iii-trial-of-carboplatin-and-paclitaxel-compared-with-cisplatin-and-paclitaxel-in-patients-with-optimally-resected 2026-06-19 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=630&slug=cyclophosphamide-and-cisplatin-compared-with-paclitaxel-and-cisplatin-in-patients-with-stage-iii-and-stage-iv-ovarian-ca 2026-06-19 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=629&slug=circulating-tumor-dna-guided-adjuvant-therapy-in-locally-advanced-colon-cancer-the-randomized-phase-2-3-dynamic-iii-tria 2026-06-18 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=628&slug=adjuvant-chemoradiotherapy-versus-completion-total-mesorectal-excision-after-local-excision-for-early-rectal-cancer-tesa 2026-06-18 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=627&slug=abiraterone-for-prostate-cancer-not-previously-treated-with-hormone-therapy 2026-06-18 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=625&slug=hypofractionated-dose-escalation-versus-conventionally-fractionated-radiation-therapy-for-patients-with-intermediate-and 2026-06-18 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=626&slug=conventional-versus-hypofractionated-high-dose-intensity-modulated-radiotherapy-for-prostate-cancer-5-year-outcomes-of-t 2026-06-18 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=624&slug=prostate-only-versus-whole-pelvic-radiation-therapy-in-high-risk-and-very-high-risk-prostate-cancer-pop-rt-outcomes-from 2026-06-18 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=623&slug=overall-survival-from-the-open-label-phase-ii-trial-of-palbociclib-in-patients-with-advanced-well-differentiated-dediffe 2026-06-18 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=622&slug=ivonescimab-plus-chemotherapy-versus-tislelizumab-plus-chemotherapy-as-first-line-treatment-for-advanced-squamous-non-sm 2026-06-18 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=621&slug=effect-of-radiotherapy-alone-vs-radiotherapy-with-concurrent-chemoradiotherapy-on-survival-without-disease-relapse-in-pa 2026-06-17 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=615&slug=randomized-phase-iii-trial-of-metabolic-imaging-guided-dose-escalation-of-radio-chemotherapy-in-patients-with-newly-diag 2026-06-17 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=616&slug=radiotherapy-combined-with-nivolumab-or-temozolomide-for-newly-diagnosed-glioblastoma-with-unmethylated-mgmt-promoter-an 2026-06-17 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=617&slug=phase-iii-trial-of-chemoradiotherapy-with-temozolomide-plus-nivolumab-or-placebo-for-newly-diagnosed-glioblastoma-with-m 2026-06-17 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=618&slug=temozolomide-and-radiotherapy-versus-radiotherapy-alone-in-patients-with-glioblastoma-idh-wildtype-post-hoc-analysis-of- 2026-06-17 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=619&slug=depatuxizumab-mafodotin-in-egfr-amplified-newly-diagnosed-glioblastoma-a-phase-iii-randomized-clinical-trial 2026-06-17 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=620&slug=use-of-5-ala-fluorescence-guided-surgery-versus-white-light-conventional-microsurgery-for-the-resection-of-newly-diagnos 2026-06-17 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=612&slug=stellar-phase-iii-randomized-open-label-study-of-eflornithine-plus-lomustine-versus-lomustine-alone-in-patients-with-rec 2026-06-17 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=613&slug=dual-immune-check-point-blockade-in-mgmt-unmethylated-newly-diagnosed-glioblastoma-nrg-oncology-bn007-a-randomized-phase 2026-06-17 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=614&slug=vebreltinib-for-previously-treated-astrocytoma-idh-mutant-grade-4-and-glioblastoma-idh-wild-type-with-ptprz1-met-fusion- 2026-06-17 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=611&slug=final-outcomes-of-the-soft-and-text-phase-iii-trials-in-premenopausal-hormone-receptor-positive-early-breast-cancer 2026-06-17 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=610&slug=hormone-therapy-use-and-duration-with-postoperative-radiotherapy-for-recurrent-prostate-cancer-an-individual-patient-dat 2026-06-17 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=609&slug=presto-a-phase-iii-open-label-study-of-intensification-of-androgen-blockade-in-patients-with-high-risk-biochemically-rel 2026-06-17 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=608&slug=overall-survival-in-patients-with-metastatic-castration-sensitive-prostate-cancer-treated-with-apalutamide-versus-abirat 2026-06-17 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=607&slug=effect-of-longer-interval-vs-standard-dosing-of-zoledronic-acid-on-skeletal-events-in-patients-with-bone-metastases-a-ra 2026-06-16 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=605&slug=endometrial-cancer-esmo-clinical-practice-guideline-for-diagnosis-treatment-and-follow-up 2026-06-16 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=604&slug=duration-of-androgen-deprivation-therapy-with-postoperative-radiotherapy-for-prostate-cancer-a-comparison-of-long-course 2026-06-16 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=603&slug=physical-examinations-and-whole-body-imaging-versus-physical-examinations-alone-during-follow-up-after-radical-surgery-o 2026-06-16 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=602&slug=cytoreductive-surgery-with-or-without-hyperthermic-intraperitoneal-chemotherapy-in-patients-with-advanced-ovarian-cancer 2026-06-16 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=601&slug=veliparib-concomitant-with-first-line-chemotherapy-and-as-maintenance-therapy-in-ovarian-cancer-final-overall-survival-a 2026-06-16 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=600&slug=overall-survival-with-relacorilant-and-nab-paclitaxel-in-patients-with-platinum-resistant-ovarian-cancer-rosella-a-phase 2026-06-16 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=599&slug=trastuzumab-deruxtecan-for-human-epidermal-growth-factor-receptor-2-expressing-advanced-or-recurrent-uterine-carcinosarc 2026-06-16 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=598&slug=ten-year-results-of-the-portec-2-trial-for-high-intermediate-risk-endometrial-carcinoma-improving-patient-ion-for-adjuva 2026-06-16 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=597&slug=efficacy-and-safety-of-trastuzumab-deruxtecan-in-patients-with-her2-expressing-solid-tumors-primary-results-from-the-des 2026-06-16 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=596&slug=effect-of-radiotherapy-after-mastectomy-and-axillary-surgery-on-10-year-recurrence-and-20-year-breast-cancer-mortality-m 2026-06-16 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=595&slug=pembrolizumab-plus-weekly-paclitaxel-in-platinum-resistant-recurrent-ovarian-cancer-engot-ov65-keynote-b96-a-multicentre 2026-06-16 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=594&slug=adjuvant-pertuzumab-and-trastuzumab-in-early-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-in-the-aphi 2026-06-16 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=593&slug=maintenance-chemotherapy-in-patients-with-high-risk-rhabdomyosarcoma-long-term-survival-analysis-of-the-paediatric-europ 2026-06-16 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=592&slug=3-versus-6-months-of-adjuvant-oxaliplatin-fluoropyrimidine-combination-therapy-for-colorectal-cancer-scot-an-internation 2026-06-15 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=591&slug=duration-of-adjuvant-chemotherapy-for-stage-iii-colon-cancer 2026-06-15 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=590&slug=oxaliplatin-fluorouracil-and-leucovorin-as-adjuvant-treatment-for-colon-cancer 2026-06-15 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=589&slug=regorafenib-monotherapy-for-previously-treated-metastatic-colorectal-cancer-correct-an-international-multicentre-randomi 2026-06-14 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=588&slug=hyperfractionation-compared-with-standard-fractionation-in-intensity-modulated-radiotherapy-for-patients-with-locally-ad 2026-06-14 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=587&slug=177lu-lu-psma-617-plus-enzalutamide-in-patients-with-metastatic-castration-resistant-prostate-cancer-enza-p-an-open-labe 2026-06-14 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=586&slug=efficacy-and-safety-of-first-line-maintenance-therapy-with-lurbinectedin-plus-atezolizumab-in-extensive-stage-small-cell 2026-06-14 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=584&slug=early-toxicity-of-moderately-hypofractionated-radiation-therapy-in-breast-cancer-patients-receiving-locoregional-irradia 2026-06-14 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=583&slug=capecitabine-or-capecitabine-plus-oxaliplatin-versus-fluorouracil-plus-cisplatin-in-definitive-concurrent-chemoradiother 2026-06-13 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=582&slug=long-term-analysis-of-nrg-oncology-rtog-0539-a-phase-ii-trial-of-observation-for-low-risk-meningioma-and-radiotherapy-fo 2026-06-13 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=581&slug=addition-of-aflibercept-to-fluorouracil-leucovorin-and-irinotecan-improves-survival-in-a-phase-iii-randomized-trial-in-p 2026-06-13 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=580&slug=continuation-of-bevacizumab-after-first-progression-in-metastatic-colorectal-cancer-ml18147-a-randomised-phase-3-trial 2026-06-13 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=579&slug=initial-therapy-with-folfoxiri-and-bevacizumab-for-metastatic-colorectal-cancer 2026-06-13 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=578&slug=neoadjuvant-and-adjuvant-pembrolizumab-plus-chemotherapy-in-locally-advanced-gastric-or-gastrooesophageal-cancer-keynote 2026-06-13 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=577&slug=radiation-plus-procarbazine-ccnu-and-vincristine-in-low-grade-glioma 2026-06-13 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=576&slug=vorasidenib-in-idh1-or-idh2-mutant-low-grade-glioma 2026-06-13 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=575&slug=peak-a-randomized-multicenter-phase-ii-study-of-panitumumab-plus-modified-fluorouracil-leucovorin-and-oxaliplatin-mfolfo 2026-06-12 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=574&slug=panitumumab-plus-5-fluorouracil-and-folinic-acid-or-5-fluorouracil-and-folinic-acid-alone-as-maintenance-therapy-in-ras- 2026-06-12 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=573&slug=fluorouracil-leucovorin-and-irinotecan-plus-cetuximab-versus-cetuximab-as-maintenance-therapy-in-first-line-therapy-for- 2026-06-12 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=572&slug=radiation-dose-intensification-in-locally-advanced-rectal-cancer-multicenter-retrospective-analysis-on-pathological-comp 2026-06-12 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=571&slug=upfront-modified-folfoxiri-plus-panitumumab-for-ras-braf-wild-type-metastatic-colorectal-cancer-final-results-of-the-pha 2026-06-12 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=570&slug=cetuximab-and-chemotherapy-as-initial-treatment-for-metastatic-colorectal-cancer 2026-06-11 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=569&slug=panitumumab-folfox4-treatment-and-ras-mutations-in-colorectal-cancer 2026-06-11 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=568&slug=folfiri-plus-cetuximab-or-bevacizumab-for-advanced-colorectal-cancer-final-survival-and-per-protocol-analysis-of-fire-3- 2026-06-11 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=567&slug=encorafenib-binimetinib-and-cetuximab-in-braf-v600e-mutated-colorectal-cancer 2026-06-11 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=566&slug=optimox1-a-randomized-study-of-folfox4-or-folfox7-with-oxaliplatin-in-a-stop-and-go-fashion-in-advanced-colorectal-cance 2026-06-11 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=565&slug=a-randomized-phase-iii-clinical-trial-of-weekly-versus-tri-weekly-cisplatin-based-chemoradiotherapy-for-locally-advanced 2026-06-11 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=564&slug=final-results-of-destiny-crc01-investigating-trastuzumab-deruxtecan-in-patients-with-her2-expressing-metastatic-colorect 2026-06-11 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=563&slug=organ-preservation-with-chemoradiotherapy-plus-local-excision-for-rectal-cancer-5-year-results-of-the-greccar-2-randomis 2026-06-11 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=562&slug=long-term-oncological-and-functional-outcomes-of-chemoradiotherapy-followed-by-organ-sparing-transanal-endoscopic-micros 2026-06-11 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=561&slug=organ-preservation-for-clinical-t2n0-distal-rectal-cancer-using-neoadjuvant-chemoradiotherapy-and-local-excision-results 2026-06-11 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=560&slug=pd-1-blockade-in-mismatch-repair-deficient-locally-advanced-rectal-cancer 2026-06-10 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=557&slug=survival-following-liver-transplantation-for-patients-with-nonresectable-liver-only-colorectal-metastases 2026-06-09 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=556&slug=neoadjuvant-chemotherapy-with-capox-versus-chemoradiation-for-locally-advanced-rectal-cancer-with-uninvolved-mesorectal- 2026-06-09 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=555&slug=folfiri-followed-by-folfox6-or-the-reverse-sequence-in-advanced-colorectal-cancer-a-randomized-gercor-study 2026-06-09 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=554&slug=tumor-debulking-in-combination-with-chemotherapy-in-multiorgan-metastatic-colorectal-cancer-the-orchestra-randomized-cli 2026-06-09 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=553&slug=hypofractionated-vs-conventionally-fractionated-postmastectomy-radiation-after-implant-based-reconstruction-a-randomized 2026-06-09 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=552&slug=70-gene-signature-as-an-aid-for-treatment-decisions-in-early-breast-cancer-updated-results-of-the-phase-3-randomised-min 2026-06-09 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=551&slug=randomized-controlled-trial-of-irinotecan-plus-infusional-bolus-or-oral-fluoropyrimidines-in-first-line-treatment-of-met 2026-06-09 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=550&slug=long-course-preoperative-chemoradiation-versus-5-x-5-gy-and-consolidation-chemotherapy-for-clinical-t4-and-fixed-clinica 2026-06-09 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=549&slug=the-role-of-maintenance-strategies-in-metastatic-colorectal-cancer-a-systematic-review-and-network-meta-analysis-of-rand 2026-06-09 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=548&slug=bevacizumab-maintenance-versus-no-maintenance-during-chemotherapy-free-intervals-in-metastatic-colorectal-cancer-a-rando 2026-06-09 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=547&slug=maintenance-strategies-after-first-line-oxaliplatin-plus-fluoropyrimidine-plus-bevacizumab-for-patients-with-metastatic- 2026-06-09 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=546&slug=maintenance-treatment-with-capecitabine-and-bevacizumab-in-metastatic-colorectal-cancer-cairo3-a-phase-3-randomised-cont 2026-06-09 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=545&slug=panitumumab-vs-bevacizumab-added-to-standard-first-line-chemotherapy-and-overall-survival-among-patients-with-ras-wild-t 2026-06-09 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=544&slug=pembrolizumab-in-microsatellite-instability-high-advanced-colorectal-cancer 2026-06-09 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=543&slug=nivolumab-plus-ipilimumab-in-microsatellite-instability-high-metastatic-colorectal-cancer 2026-06-09 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=542&slug=late-line-options-for-patients-with-metastatic-colorectal-cancer-a-review-and-evidence-based-algorithm 2026-06-09 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=541&slug=upfront-resection-versus-no-resection-of-the-primary-tumor-in-patients-with-synchronous-metastatic-colorectal-cancer-the 2026-06-09 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=540&slug=trifluridine-tipiracil-and-bevacizumab-in-refractory-metastatic-colorectal-cancer 2026-06-09 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=539&slug=randomized-trial-of-tas-102-for-refractory-metastatic-colorectal-cancer 2026-06-09 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=538&slug=overall-survival-with-pembrolizumab-in-early-stage-triple-negative-breast-cancer 2026-06-08 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=537&slug=impact-of-adjuvant-radiotherapy-on-survival-of-patients-with-node-positive-prostate-cancer 2026-06-08 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=536&slug=the-addition-of-androgen-deprivation-therapy-and-pelvic-lymph-node-treatment-to-prostate-bed-salvage-radiotherapy-nrg-on 2026-06-08 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=534&slug=adjuvant-versus-early-salvage-radiation-therapy-after-radical-prostatectomy-for-pn1-prostate-cancer-and-the-risk-of-deat 2026-06-08 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=535&slug=adjuvant-or-early-salvage-radiotherapy-for-the-treatment-of-localised-and-locally-advanced-prostate-cancer-a-prospective 2026-06-08 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=533&slug=salvage-radiotherapy-confers-an-overall-survival-advantage-in-biochemical-recurrence-of-prostate-cancer-evidence-from-th 2026-06-08 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=529&slug=nanoliposomal-irinotecan-with-fluorouracil-and-folinic-acid-in-metastatic-pancreatic-cancer-after-previous-gemcitabine-b 2026-06-08 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=530&slug=folfirinox-versus-gemcitabine-for-metastatic-pancreatic-cancer 2026-06-08 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=531&slug=nalirifox-versus-nab-paclitaxel-and-gemcitabine-in-treatment-naive-patients-with-metastatic-pancreatic-ductal-adenocarci 2026-06-08 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=532&slug=nab-paclitaxel-plus-gemcitabine-for-metastatic-pancreatic-cancer-long-term-survival-from-a-phase-iii-trial 2026-06-08 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=527&slug=five-year-outcomes-of-folfirinox-vs-gemcitabine-as-adjuvant-therapy-for-pancreatic-cancer-a-randomized-clinical-trial 2026-06-08 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=528&slug=adjuvant-nab-paclitaxel-gemcitabine-in-resected-pancreatic-ductal-adenocarcinoma-results-from-a-randomized-open-label-ph 2026-06-08 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=525&slug=long-term-results-and-recurrence-patterns-from-scalop-a-phase-ii-randomised-trial-of-gemcitabine-or-capecitabine-based-c 2026-06-08 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=526&slug=effect-of-chemoradiotherapy-vs-chemotherapy-on-survival-in-patients-with-locally-advanced-pancreatic-cancer-controlled-a 2026-06-08 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=520&slug=overall-survival-with-maintenance-olaparib-at-a-7-year-follow-up-in-patients-with-newly-diagnosed-advanced-ovarian-cance 2026-06-08 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=521&slug=niraparib-first-line-maintenance-therapy-in-patients-with-newly-diagnosed-advanced-ovarian-cancer-final-overall-survival 2026-06-08 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=522&slug=rucaparib-maintenance-for-newly-diagnosed-advanced-ovarian-cancer-interim-overall-survival-progression-free-survival-and 2026-06-08 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=523&slug=updated-progression-free-survival-and-final-overall-survival-with-maintenance-olaparib-plus-bevacizumab-according-to-cli 2026-06-08 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=518&slug=adjuvant-paclitaxel-and-trastuzumab-for-node-negative-her2-positive-breast-cancer 2026-06-08 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=519&slug=adjuvant-trastuzumab-emtansine-versus-paclitaxel-in-combination-with-trastuzumab-for-stage-i-her2-positive-breast-cancer 2026-06-08 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=517&slug=final-results-of-an-eortc-gu-cancers-group-randomized-study-of-maintenance-bacillus-calmette-guerin-in-intermediate-and- 2026-06-07 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=516&slug=radical-cystectomy-versus-trimodality-therapy-for-muscleinvasive-bladder-cancer-a-multi-institutional-propensity-score-m 2026-06-07 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=515&slug=nonoperative-management-of-mismatch-repair-deficient-tumors 2026-06-07 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=514&slug=radiographic-progression-with-and-without-prostate-specific-antigen-rise-in-patients-with-advanced-prostate-cancer-treat 2026-06-07 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=513&slug=neoadjuvant-durvalumab-improves-survival-in-early-triple-negative-breast-cancer-independent-of-pathological-complete-res 2026-06-07 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=512&slug=nsabp-b-47-nrg-oncology-phase-iii-randomized-trial-comparing-adjuvant-chemotherapy-with-or-without-trastuzumab-in-high-r 2026-06-07 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=507&slug=neoadjuvant-chemotherapy-with-trastuzumab-followed-by-adjuvant-trastuzumab-versus-neoadjuvant-chemotherapy-alone-in-pati 2026-06-07 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=508&slug=three-year-follow-up-of-neoadjuvant-chemotherapy-with-or-without-anthracyclines-in-the-presence-of-dual-erbb2-blockade-i 2026-06-07 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=509&slug=6-months-versus-12-months-of-adjuvant-trastuzumab-in-early-breast-cancer-phare-final-analysis-of-a-multicentre-open-labe 2026-06-07 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=510&slug=6-versus-12-months-of-adjuvant-trastuzumab-for-her2-positive-early-breast-cancer-persephone-4-year-disease-free-survival 2026-06-07 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=511&slug=trastuzumab-emtansine-plus-pertuzumab-versus-taxane-plus-trastuzumab-plus-pertuzumab-after-anthracycline-for-high-risk-h 2026-06-07 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=505&slug=impact-of-anthracyclines-in-genomic-high-risk-node-negative-hr-positive-her2-negative-breast-cancer 2026-06-07 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=506&slug=neoadjuvant-nivolumab-and-chemotherapy-in-early-estrogen-receptor-positive-breast-cancer-a-randomized-phase-3-trial 2026-06-07 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=504&slug=final-overall-survival-and-molecular-data-associated-with-clinical-outcomes-in-patients-receiving-ipatasertib-and-abirat 2026-06-07 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=503&slug=perioperative-pembrolizumab-for-early-stage-non-small-cell-lung-cancer 2026-06-07 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=502&slug=pembrolizumab-plus-chemotherapy-versus-placebo-plus-chemotherapy-for-her2-negative-advanced-gastric-cancer-keynote-859-a 2026-06-07 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=501&slug=sacituzumab-govitecan-in-untreated-advanced-triple-negative-breast-cancer 2026-06-07 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=498&slug=addition-of-carboplatin-to-sequential-taxane-anthracycline-neoadjuvant-chemotherapy-in-triple-negative-breast-cancer-a-p 2026-06-07 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=499&slug=effect-of-adjuvant-carboplatin-intensified-chemotherapy-versus-standard-chemotherapy-on-survival-in-women-with-high-risk 2026-06-07 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=500&slug=metronomic-capecitabine-as-extended-adjuvant-chemotherapy-for-early-triple-negative-breast-cancer-sysucc-001-updated-10- 2026-06-07 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=488&slug=docetaxel-plus-prednisone-or-mitoxantrone-plus-prednisone-for-advanced-prostate-cancer 2026-06-07 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=489&slug=prednisone-plus-cabazitaxel-or-mitoxantrone-for-metastatic-castration-resistant-prostate-cancer-progressing-after-doceta 2026-06-07 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=490&slug=cabazitaxel-versus-abiraterone-or-enzalutamide-in-metastatic-prostate-cancer 2026-06-07 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=491&slug=abiraterone-acetate-plus-prednisone-versus-placebo-plus-prednisone-in-chemotherapy-naive-men-with-metastatic-castration- 2026-06-07 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=492&slug=enzalutamide-in-metastatic-prostate-cancer-before-chemotherapy 2026-06-07 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=493&slug=increased-survival-with-enzalutamide-in-prostate-cancer-after-chemotherapy 2026-06-07 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=494&slug=alpha-emitter-radium-223-and-survival-in-metastatic-prostate-cancer 2026-06-07 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=495&slug=abiraterone-and-increased-survival-in-metastatic-prostate-cancer 2026-06-07 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=496&slug=sipuleucel-t-immunotherapy-for-castration-resistant-prostate-cancer 2026-06-07 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=497&slug=abiraterone-alone-or-in-combination-with-enzalutamide-in-metastatic-castration-resistant-prostate-cancer-with-rising-pro 2026-06-07 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=485&slug=extending-the-duration-of-endocrine-treatment-for-early-breast-cancer-patient-level-meta-analysis-of-12-randomised-trial 2026-06-07 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=486&slug=outcomes-of-anastrozole-letrozole-and-exemestane-in-patients-with-postmenopausal-breast-cancer 2026-06-07 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=483&slug=lumpectomy-plus-tamoxifen-with-or-without-irradiation-in-women-age-70-years-or-older-with-early-breast-cancer-long-term- 2026-06-07 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=480&slug=nivolumab-and-ipilimumab-as-maintenance-therapy-in-extensive-disease-small-cell-lung-cancer-checkmate-451 2026-06-06 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=481&slug=randomized-phase-ii-clinical-trial-of-cisplatin-carboplatin-and-etoposide-pe-alone-or-in-combination-with-nivolumab-as-f 2026-06-06 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=482&slug=pembrolizumab-or-placebo-plus-etoposide-and-platinum-as-first-line-therapy-for-extensive-stage-small-cell-lung-cancer-ra 2026-06-06 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=479&slug=overall-survival-with-first-line-vs-second-line-cdk4-6-inhibitor-use-in-advanced-breast-cancer-a-randomized-clinical-tri 2026-06-06 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=478&slug=adding-metastasis-directed-therapy-to-standard-of-care-systemic-therapy-for-oligometastatic-breast-cancer-extend-a-multi 2026-06-06 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=477&slug=early-local-therapy-for-the-primary-site-in-de-novo-stage-iv-breast-cancer-results-of-a-randomized-clinical-trial-ea2108 2026-06-06 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=476&slug=bladder-adjuvant-radiotherapy-phase-iii-multicenter-randomized-controlled-trial-of-adjuvant-radiotherapy-or-observation- 2026-06-06 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=475&slug=stereotactic-body-radiation-therapy-and-abiraterone-acetate-for-patients-affected-by-oligometastatic-castrate-resistant- 2026-06-06 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=474&slug=adjuvant-nivolumab-plus-chemotherapy-versus-placebo-plus-chemotherapy-for-stage-iii-gastric-or-gastro-oesophageal-juncti 2026-06-06 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=472&slug=high-dose-hyperfractionated-simultaneous-integrated-boost-radiotherapy-versus-standard-dose-radiotherapy-for-limited-sta 2026-06-06 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=473&slug=moderately-hypofractionated-once-daily-compared-with-twice-daily-thoracic-radiation-therapy-concurrently-with-etoposide- 2026-06-06 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=471&slug=internal-mammary-and-medial-supraclavicular-lymph-node-chain-irradiation-in-stage-i-iii-breast-cancer-eortc-22922-10925- 2026-06-06 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=469&slug=gastric-lymph-node-contouring-atlas-a-tool-to-aid-in-clinical-target-volume-definition-in-3-dimensional-treatment-planni 2026-06-06 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=468&slug=estro-acrop-guidelines-for-target-volume-definition-in-the-thoracic-radiation-treatment-of-small-cell-lung-cancer 2026-06-06 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=467&slug=estro-acrop-guidelines-for-target-volume-definition-in-the-treatment-of-locally-advanced-non-small-cell-lung-cancer 2026-06-06 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=466&slug=estro-consensus-guidelines-on-gtv-delineation-and-dose-escalation-in-rectal-cancer 2026-06-06 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=464&slug=nrg-oncology-updated-international-consensus-atlas-on-pelvic-lymph-node-volumes-for-intact-and-postoperative-prostate-ca 2026-06-06 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=465&slug=estro-acrop-guideline-on-prostate-bed-delineation-for-postoperative-radiotherapy-in-prostate-cancer 2026-06-06 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=463&slug=breast-cancer-atlas-for-radiation-therapy-planning-consensus-definitions 2026-06-06 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=462&slug=capivasertib-plus-abiraterone-in-pten-deficient-metastatic-hormone-sensitive-prostate-cancer-capitello-281-phase-iii-stu 2026-06-06 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=461&slug=international-consensus-guidelines-for-adjuvant-radiation-therapy-for-bladder-cancer-after-radical-cystectomy-update-fro 2026-06-05 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=460&slug=estro-eano-guideline-on-target-delineation-and-radiotherapy-details-for-idh-mutant-grade-2-and-grade-3-diffuse-gliomas 2026-06-05 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=459&slug=consensus-guidelines-for-delineation-of-clinical-target-volumes-for-intensity-modulated-radiotherapy-for-intact-cervical 2026-06-05 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=458&slug=nrg-oncology-rtog-consensus-guidelines-for-delineation-of-clinical-target-volume-for-intensity-modulated-pelvic-radiatio 2026-06-05 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=456&slug=delineation-of-the-primary-tumour-clinical-target-volumes-ctv-p-in-laryngeal-hypopharyngeal-oropharyngeal-and-oral-cavit 2026-06-05 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=454&slug=delineation-of-the-neck-node-levels-for-head-and-neck-tumors-a-2013-update-dahanca-eortc-hknpcsg-ncic-ctg-ncri-rtog-trog 2026-06-05 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=455&slug=delineation-of-the-neck-node-levels-for-head-and-neck-tumors-a-2013-update-dahanca-eortc-hknpcsg-ncic-ctg-ncri-rtog-trog 2026-06-05 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=452&slug=international-consensus-guidelines-on-clinical-target-volume-delineation-in-rectal-cancer 2026-06-05 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=453&slug=international-consensus-guidelines-on-clinical-target-volume-delineation-in-rectal-cancer-atlas 2026-06-05 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=451&slug=the-iaslc-lung-cancer-staging-project-a-proposal-for-a-new-international-lymph-node-map-in-the-forthcoming-seventh-editi 2026-06-05 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=450&slug=estro-acrop-consensus-guideline-on-ct-and-mri-based-target-volume-delineation-for-primary-radiation-therapy-of-localized 2026-06-05 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=449&slug=delineation-of-the-post-operative-primary-tumour-and-nodal-clinical-target-volumes-in-oral-cavity-squamous-cell-carcinom 2026-06-05 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=445&slug=target-volume-delineation-of-the-neck-for-radiotherapy-in-nasopharyngeal-carcinoma-cstro-caca-csco-hncig-estro-and-astro 2026-06-05 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=446&slug=international-consensus-guideline-on-delineation-of-the-clinical-target-volumes-at-different-dose-levels-for-nasopharyng 2026-06-05 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=447&slug=target-volume-delineation-of-the-neck-for-radiotherapy-in-nasopharyngeal-carcinoma-cstro-caca-csco-hncig-estro-and-astro 2026-06-05 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=448&slug=primary-target-volume-delineation-for-radiotherapy-in-nasopharyngeal-carcinoma-cstro-caca-csco-hncig-estro-and-astro-gui 2026-06-05 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=444&slug=primary-target-volume-delineation-for-radiotherapy-in-nasopharyngeal-carcinoma-cstro-caca-csco-hncig-estro-and-astro-gui 2026-06-05 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=443&slug=estro-eano-guideline-on-target-delineation-and-radiotherapy-details-for-glioblastoma 2026-06-05 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=442&slug=sasanlimab-plus-bcg-in-bcg-naive-high-risk-non-muscle-invasive-bladder-cancer-the-randomized-phase-3-crest-trial 2026-06-04 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=441&slug=hypofractionated-dose-escalation-radiotherapy-for-high-risk-prostate-cancer-the-survival-analysis-of-the-prostate-cancer 2026-06-04 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=440&slug=hypofractionated-breast-radiotherapy-for-1-week-versus-3-weeks-fast-forward-10-year-efficacy-and-late-normal-tissue-effe 2026-06-04 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=439&slug=aglatimagene-besadenovec-can-2409-with-radiotherapy-for-patients-with-localised-prostate-cancer-a-phase-3-multicentre-ra 2026-06-04 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=438&slug=osimertinib-after-chemoradiotherapy-in-stage-iii-egfr-mutated-nsclc 2026-06-04 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=437&slug=fluorouracil-based-adjuvant-chemotherapy-after-preoperative-chemoradiotherapy-in-rectal-cancer-long-term-results-of-the- 2026-06-04 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=436&slug=adjuvant-capecitabine-following-concurrent-chemoradiotherapy-in-locoregionally-advanced-nasopharyngeal-carcinoma-a-rando 2026-06-03 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=434&slug=avelumab-first-line-maintenance-for-advanced-urothelial-carcinoma-results-from-the-javelin-bladder-100-trial-after-2-yea 2026-06-02 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=435&slug=three-versus-six-cycles-of-platinum-based-chemotherapy-followed-by-avelumab-maintenance-as-first-line-treatment-for-adva 2026-06-02 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=433&slug=safety-and-efficacy-of-pembrolizumab-radiation-therapy-and-surgery-versus-radiation-therapy-and-surgery-for-stage-iii-so 2026-06-02 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=432&slug=feasibility-of-preoperative-chemotherapy-with-or-without-radiation-therapy-in-localized-soft-tissue-sarcomas-of-limbs-an 2026-06-02 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=431&slug=ifosfamide-in-the-adjuvant-therapy-of-soft-tissue-sarcomas 2026-06-02 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=430&slug=doxorubicin-alone-versus-intensified-doxorubicin-plus-ifosfamide-for-first-line-treatment-of-advanced-or-metastatic-soft 2026-06-02 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=429&slug=first-line-camizestrant-for-emerging-esr1-mutated-advanced-breast-cancer 2026-06-01 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=419&slug=locoregional-failure-during-and-after-short-course-radiotherapy-followed-by-chemotherapy-and-surgery-compared-with-long- 2026-06-01 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=420&slug=short-course-radiotherapy-followed-by-chemotherapy-before-total-mesorectal-excision-tme-versus-preoperative-chemoradioth 2026-06-01 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=422&slug=chemotherapy-with-preoperative-radiotherapy-in-rectal-cancer 2026-06-01 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=423&slug=chemotherapy-before-or-after-preoperative-chemoradiotherapy-and-surgery-for-locally-advanced-rectal-cancer-5-year-result 2026-06-01 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=424&slug=total-neoadjuvant-therapy-with-mfolfirinox-versus-preoperative-chemoradiotherapy-in-patients-with-locally-advanced-recta 2026-06-01 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=425&slug=preoperative-treatment-of-locally-advanced-rectal-cancer 2026-06-01 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=426&slug=multicenter-randomized-phase-iii-trial-of-short-term-radiotherapy-plus-chemotherapy-versus-long-term-chemoradiotherapy-i 2026-06-01 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=427&slug=long-term-results-of-organ-preservation-in-patients-with-rectal-adenocarcinoma-treated-with-total-neoadjuvant-therapy-th 2026-06-01 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=428&slug=preoperative-radiotherapy-combined-with-total-mesorectal-excision-for-resectable-rectal-cancer 2026-06-01 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=418&slug=transdermal-estradiol-patches-in-locally-advanced-prostate-cancer 2026-05-31 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=414&slug=adjuvant-lymph-node-field-radiotherapy-versus-observation-only-in-patients-with-melanoma-at-high-risk-of-further-lymph-n 2026-05-31 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=415&slug=final-analysis-of-decog-slt-trial-no-survival-benefit-for-complete-lymph-node-dissection-in-patients-with-melanoma-with- 2026-05-31 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=410&slug=dabrafenib-plus-trametinib-versus-dabrafenib-monotherapy-in-patients-with-metastatic-braf-v600e-k-mutant-melanoma-long-t 2026-05-31 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=411&slug=five-year-outcomes-with-dabrafenib-plus-trametinib-in-metastatic-melanoma 2026-05-31 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=412&slug=5-year-outcomes-with-cobimetinib-plus-vemurafenib-in-brafv600-mutation-positive-advanced-melanoma-extended-follow-up-of- 2026-05-31 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=413&slug=seven-year-outcomes-with-encorafenib-plus-binimetinib-in-patients-with-braf-v600e-k-mutant-advanced-melanoma-long-term-f 2026-05-31 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=409&slug=daraxonrasib-or-chemotherapy-in-previously-treated-metastatic-pancreatic-cancer 2026-05-31 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=408&slug=selpercatinib-in-early-stage-ret-fusion-positive-non-small-cell-lung-cancer 2026-05-31 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=407&slug=perioperative-apalutamide-in-high-risk-localized-prostate-cancer 2026-05-31 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=406&slug=structured-exercise-after-adjuvant-chemotherapy-for-colon-cancer 2026-05-31 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=405&slug=ctdna-guided-adjuvant-atezolizumab-in-muscle-invasive-bladder-cancer 2026-05-31 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=404&slug=disitamab-vedotin-plus-toripalimab-in-her2-expressing-advanced-urothelial-cancer 2026-05-31 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=403&slug=ten-year-survival-after-postmastectomy-chest-wall-irradiation-in-breast-cancer 2026-05-31 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=402&slug=total-neoadjuvant-treatment-using-short-course-radiotherapy-and-four-capox-cycles-in-locally-advanced-rectal-cancer-with 2026-05-31 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=401&slug=aumolertinib-as-adjuvant-therapy-in-resected-egfr-mutated-non-small-cell-lung-cancer-arts-a-double-blind-multicentre-ran 2026-05-31 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=400&slug=phase-iii-study-of-mediastinal-lymph-node-dissection-for-ground-glass-opacity-dominant-lung-adenocarcinoma 2026-05-31 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=399&slug=thoracic-radiotherapy-improves-the-survival-in-patients-with-egfr-mutated-oligo-organ-metastatic-non-small-cell-lung-can 2026-05-31 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=395&slug=combination-dabrafenib-and-trametinib-versus-combination-nivolumab-and-ipilimumab-for-patients-with-advanced-braf-mutant 2026-05-31 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=396&slug=randomized-phase-iii-trial-evaluating-spartalizumab-plus-dabrafenib-and-trametinib-for-braf-v600-mutant-unresectable-or- 2026-05-31 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=397&slug=atezolizumab-vemurafenib-and-cobimetinib-as-first-line-treatment-for-unresectable-advanced-brafv600-mutation-positive-me 2026-05-31 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=394&slug=concurrent-and-adjuvant-temozolomide-for-1p-19q-non-co-d-anaplastic-glioma-catnon-eortc-study-26053-22054-final-and-expl 2026-05-31 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=393&slug=encorafenib-cetuximab-and-mfolfox6-in-braf-mutated-colorectal-cancer 2026-05-31 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=391&slug=low-dose-aspirin-for-pi3k-altered-localized-colorectal-cancer 2026-05-31 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=392&slug=atezolizumab-plus-folfox-for-stage-iii-mismatch-repair-deficient-colon-cancer 2026-05-31 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=389&slug=phase-3-trial-of-stereotactic-body-radiotherapy-in-localized-prostate-cancer 2026-05-31 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=390&slug=radical-prostatectomy-versus-stereotactic-radiotherapy-for-clinically-localised-prostate-cancer-results-of-the-pace-a-ra 2026-05-31 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=387&slug=vincristine-actinomycin-and-cyclophosphamide-compared-with-vincristine-actinomycin-and-cyclophosphamide-alternating-with 2026-05-31 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=388&slug=addition-of-vincristine-and-irinotecan-to-vincristine-dactinomycin-and-cyclophosphamide-does-not-improve-outcome-for-int 2026-05-31 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=386&slug=romiplostim-versus-placebo-for-chemotherapy-induced-thrombocytopenia 2026-05-31 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=385&slug=adjuvant-nivolumab-and-relatlimab-in-stage-iii-iv-melanoma-the-randomized-phase-3-relativity-098-trial 2026-05-31 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=382&slug=pembrolizumab-versus-ipilimumab-for-advanced-melanoma-10-year-follow-up-of-the-phase-iii-keynote-006-study 2026-05-31 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=383&slug=three-year-overall-survival-with-nivolumab-plus-relatlimab-in-advanced-melanoma-from-relativity-047 2026-05-31 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=384&slug=final-10-year-outcomes-with-nivolumab-plus-ipilimumab-in-advanced-melanoma 2026-05-31 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=381&slug=seven-year-analysis-of-adjuvant-pembrolizumab-versus-placebo-in-stage-iii-melanoma-in-the-eortc1325-keynote-054-trial 2026-05-31 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=378&slug=final-results-for-adjuvant-dabrafenib-plus-trametinib-in-stage-iii-melanoma 2026-05-31 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=379&slug=adjuvant-pembrolizumab-versus-interferon-alfa-2b-or-ipilimumab-in-resected-high-risk-melanoma 2026-05-31 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=380&slug=adjuvant-nivolumab-versus-ipilimumab-in-resected-stage-iiib-c-and-stage-iv-melanoma-checkmate-238-4-year-results-from-a- 2026-05-31 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=377&slug=alliance-a222001-oxybutynin-versus-placebo-for-the-treatment-of-hot-flashes-in-patients-receiving-androgen-deprivation-t 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=376&slug=three-versus-6-months-of-adjuvant-oxaliplatin-fluoropyrimidine-chemotherapy-for-colorectal-cancer-final-results-of-scot- 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=375&slug=randomized-phase-ii-iii-trial-comparing-hepatectomy-followed-by-mfolfox6-with-hepatectomy-alone-for-liver-metastasis-fro 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=374&slug=hyperthermic-intraperitoneal-chemotherapy-for-recurrent-ovarian-cancer-chipor-a-randomised-open-label-phase-3-trial 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=372&slug=modified-fluorouracil-leucovorin-irinotecan-and-oxaliplatin-or-s-1-irinotecan-and-oxaliplatin-versus-nab-paclitaxel-gemc 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=371&slug=tumor-treating-fields-with-gemcitabine-and-nab-paclitaxel-for-locally-advanced-pancreatic-adenocarcinoma-randomized-open 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=370&slug=lapis-a-phase-iii-randomized-placebo-controlled-double-blind-trial-of-neoadjuvant-pamrevlumab-with-chemotherapy-for-pati 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=369&slug=preoperative-mfolfirinox-versus-paxg-for-stage-i-iii-resectable-and-borderline-resectable-pancreatic-ductal-adenocarcino 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=368&slug=adjuvant-chemoradiotherapy-versus-radiotherapy-alone-in-women-with-high-risk-endometrial-cancer-portec-3-10-year-clinica 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=367&slug=molecular-profile-based-adjuvant-treatment-for-women-with-high-intermediate-risk-endometrial-cancer-portec-4a-results-of 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=366&slug=neoadjuvant-folfirinox-versus-neoadjuvant-gemcitabinebased-chemoradiotherapy-in-resectable-and-borderline-resectable-pan 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=364&slug=adjuvant-chemotherapy-and-hormonotherapy-versus-adjuvant-hormonotherapy-alone-for-women-aged-70-years-and-older-with-hig 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=357&slug=randomized-phase-ii-trial-of-carboplatin-paclitaxel-compared-with-carboplatin-paclitaxel-trastuzumab-in-advanced-stage-i 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=358&slug=lenvatinib-plus-pembrolizumab-for-advanced-endometrial-cancer 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=359&slug=dostarlimab-for-primary-advanced-or-recurrent-endometrial-cancer 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=360&slug=pembrolizumab-plus-chemotherapy-in-advanced-endometrial-cancer 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=361&slug=engot-en11-gog-3053-keynote-b21-a-randomised-double-blind-phase-iii-study-of-pembrolizumab-or-placebo-plus-adjuvant-chem 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=362&slug=durvalumab-plus-carboplatin-paclitaxel-followed-by-maintenance-durvalumab-with-or-without-olaparib-as-first-line-treatme 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=363&slug=first-line-lenvatinib-plus-pembrolizumab-versus-chemotherapy-for-advanced-endometrial-cancer-a-randomized-open-label-pha 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=355&slug=neoadjuvant-taxane-plus-trastuzumab-and-pertuzumab-with-or-without-carboplatin-in-human-epidermal-growth-factor-receptor 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=356&slug=de-escalated-neoadjuvant-weekly-nab-paclitaxel-with-trastuzumab-and-pertuzumab-versus-docetaxel-carboplatin-trastuzumab- 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=353&slug=surveillance-or-metastasis-directed-therapy-for-oligometastatic-prostate-cancer-recurrence-a-prospective-randomized-mult 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=354&slug=addition-of-metastasis-directed-therapy-to-intermittent-hormone-therapy-for-oligometastatic-prostate-cancer-the-extend-p 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=351&slug=adt-with-sbrt-versus-sbrt-alone-for-hormone-sensitive-oligorecurrent-prostate-cancer-radiosa-a-randomised-open-label-pha 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=352&slug=outcomes-of-observation-vs-stereotactic-ablative-radiation-for-oligometastatic-prostate-cancer-the-oriole-phase-2-random 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=348&slug=abiraterone-plus-prednisone-in-metastatic-castration-sensitive-prostate-cancer 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=349&slug=apalutamide-for-metastatic-castration-sensitive-prostate-cancer 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=350&slug=5-year-survival-with-enzalutamide-plus-androgen-deprivation-therapy-in-metastatic-hormone-sensitive-prostate-cancer-pati 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=347&slug=darolutamide-in-combination-with-androgen-deprivation-therapy-in-patients-with-metastatic-hormone-sensitive-prostate-can 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=346&slug=testosterone-suppression-plus-enzalutamide-versus-testosterone-suppression-plus-standard-antiandrogen-therapy-for-metast 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=343&slug=enzalutamide-and-survival-in-nonmetastatic-castration-resistant-prostate-cancer 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=344&slug=apalutamide-treatment-and-metastasis-free-survival-in-prostate-cancer 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=345&slug=darolutamide-in-nonmetastatic-castration-resistant-prostate-cancer 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=341&slug=olaparib-for-metastatic-castration-resistant-prostate-cancer 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=340&slug=177lu-lu-psma-617-versus-cabazitaxel-in-patients-with-metastatic-castration-resistant-prostate-cancer-therap-a-randomise 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=339&slug=lutetium-177-psma-617-for-metastatic-castration-resistant-prostate-cancer 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=338&slug=enzalutamide-plus-radium-223-in-metastatic-castration-resistant-prostate-cancer-results-of-the-eortc-1333-peace-3-trial 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=337&slug=177lu-psma-617-versus-a-change-of-androgen-receptor-pathway-inhibitor-therapy-for-taxane-naive-patients-with-progressive 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=336&slug=sequential-177lu-lu-psma-617-and-docetaxel-versus-docetaxel-in-patients-with-metastatic-hormone-sensitive-prostate-cance 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=335&slug=darolutamide-and-survival-in-metastatic-hormone-sensitive-prostate-cancer 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=334&slug=salvage-metastasis-directed-therapy-versus-elective-nodal-radiotherapy-for-oligorecurrent-nodal-prostate-cancer-metastas 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=333&slug=improved-survival-with-enzalutamide-in-biochemically-recurrent-prostate-cancer 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=332&slug=niraparib-and-abiraterone-acetate-plus-prednisone-for-hrr-deficient-metastatic-castration-sensitive-prostate-cancer-a-ra 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=331&slug=parp-and-androgen-signaling-inhibition-plus-adt-in-metastatic-prostate-cancer 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=330&slug=efficacy-and-safety-of-prostate-radiotherapy-in-de-novo-metastatic-castration-sensitive-prostate-cancer-peace-1-a-multic 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=328&slug=olaparib-plus-abiraterone-versus-placebo-plus-abiraterone-in-metastatic-castration-resistant-prostate-cancer-propel-fina 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=327&slug=talazoparib-plus-enzalutamide-in-men-with-first-line-metastatic-castration-resistant-prostate-cancer-talapro-2-a-randomi 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=326&slug=niraparib-plus-abiraterone-acetate-with-prednisone-in-patients-with-metastatic-castration-resistant-prostate-cancer-and- 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=325&slug=adjuvant-chemotherapy-following-chemoradiotherapy-as-primary-treatment-for-locally-advanced-cervical-cancer-versus-chemo 2026-05-30 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=324&slug=sequence-of-hormonal-therapy-and-radiotherapy-field-size-in-unfavourable-localised-prostate-cancer-nrg-rtog-9413-long-te 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=323&slug=bevacizumab-for-advanced-cervical-cancer-final-overall-survival-and-adverse-event-analysis-of-a-randomised-controlled-op 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=322&slug=simple-versus-radical-hysterectomy-in-women-with-low-risk-cervical-cancer 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=321&slug=pembrolizumab-for-persistent-recurrent-or-metastatic-cervical-cancer 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=320&slug=durvalumab-versus-placebo-with-chemoradiotherapy-for-locally-advanced-cervical-cancer-calla-a-randomised-double-blind-ph 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=319&slug=sentinel-lymph-node-biopsy-and-morbidity-outcomes-in-early-cervical-cancer-results-of-a-multicentre-randomised-trial-sen 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=318&slug=sentinel-lymph-node-biopsy-alone-or-with-lymphadenectomy-in-cervical-cancer 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=317&slug=induction-chemotherapy-followed-by-standard-chemoradiotherapy-versus-standard-chemoradiotherapy-alone-in-patients-with-l 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=316&slug=pembrolizumab-or-placebo-with-chemoradiotherapy-followed-by-pembrolizumab-or-placebo-for-newly-diagnosed-high-risk-local 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=315&slug=ramucirumab-plus-paclitaxel-as-switch-maintenance-versus-continuation-of-first-line-oxaliplatin-based-chemotherapy-in-pa 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=314&slug=long-term-prognostic-analysis-of-chemoradiation-therapy-versus-chemotherapy-after-d2-resection-for-high-risk-gastric-can 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=313&slug=pembrolizumab-plus-chemotherapy-versus-chemotherapy-alone-for-first-line-treatment-of-advanced-oesophageal-cancer-keynot 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=311&slug=abiraterone-plus-prednisone-added-to-androgen-deprivation-therapy-and-docetaxel-in-de-novo-metastatic-castration-sensiti 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=309&slug=intensity-modulated-moderately-hypofractionated-radiotherapy-versus-stereotactic-body-radiotherapy-for-prostate-cancer-p 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=308&slug=alban-getug-afu-37-a-phase-iii-randomized-open-label-international-trial-of-intravenous-atezolizumab-and-intravesical-ba 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=307&slug=durvalumab-in-combination-with-bcg-for-bcg-naive-high-risk-non-muscle-invasive-bladder-cancer-potomac-final-analysis-of- 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=306&slug=resection-the-randomized-noninferiority-phase-3-jcog1019-trial-active-surveillance-versus-intravesical-bacillus-calmette 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=305&slug=perioperative-enfortumab-vedotin-and-pembrolizumab-in-bladder-cancer 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=304&slug=enfortumab-vedotin-and-pembrolizumab-in-untreated-advanced-urothelial-cancer 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=303&slug=adjuvant-nivolumab-versus-placebo-in-muscle-invasive-urothelial-carcinoma 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=302&slug=adjuvant-pembrolizumab-versus-observation-in-muscle-invasive-urothelial-carcinoma 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=301&slug=perioperative-durvalumab-with-neoadjuvant-chemotherapy-in-operable-bladder-cancer 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=300&slug=perioperative-dose-dense-methotrexate-vinblastine-doxorubicin-and-cisplatin-in-muscle-invasive-bladder-cancer-vesper-sur 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=299&slug=high-dose-versus-standard-dose-twice-daily-thoracic-radiotherapy-in-limited-stage-small-cell-lung-cancer-final-survival- 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=297&slug=perioperative-durvalumab-for-resectable-non-small-cell-lung-cancer 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=296&slug=perioperative-nivolumab-in-resectable-lung-cancer 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=295&slug=first-line-sunvozertinib-in-nsclc-with-egfr-exon-20-insertion-mutations 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=293&slug=sacituzumab-tirumotecan-in-egfr-tki-resistant-egfr-mutated-advanced-nsclc 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=292&slug=tarlatamab-in-small-cell-lung-cancer-after-platinum-based-chemotherapy 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=291&slug=amivantamab-plus-chemotherapy-in-nsclc-with-egfr-exon-20-insertions 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=290&slug=amivantamab-plus-chemotherapy-with-and-without-lazertinib-in-egfr-mutant-advanced-nsclc-after-disease-progression-on-osi 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=289&slug=overall-survival-with-amivantamab-lazertinib-in-egfr-mutated-advanced-nsclc 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=288&slug=survival-with-osimertinib-plus-chemotherapy-in-egfr-mutated-advanced-nsclc 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=287&slug=primary-tumour-resection-plus-systemic-therapy-versus-systemic-therapy-alone-in-metastatic-breast-cancer-jcog1017-prim-b 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=286&slug=stereotactic-ablative-body-radiotherapy-for-oligoprogressive-estrogen-receptor-positive-breast-cancer-trog-20-03-avatar- 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=283&slug=consolidative-use-of-radiotherapy-to-block-curb-oligoprogression-randomised-study-of-standard-of-care-systemic-therapy-w 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=282&slug=alpelisib-plus-fulvestrant-for-pik3ca-mutated-hormone-receptor-positive-human-epidermal-growth-factor-receptor-2enegativ 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=281&slug=viktoria-1-trial-of-gedatolisib-plus-fulvestrant-with-or-without-palbociclib-in-hormone-receptor-positive-her22-pik3ca-w 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=280&slug=vepdegestrant-a-protac-estrogen-receptor-degrader-in-advanced-breast-cancer 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=279&slug=capivasertib-in-hormone-receptor-positive-advanced-breast-cancer 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=278&slug=early-versus-deferred-use-of-cdk4-6-inhibitors-in-advanced-breast-cancer 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=277&slug=trastuzumab-deruxtecan-after-endocrine-therapy-in-metastatic-breast-cancer 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=276&slug=inavolisib-based-therapy-in-pik3ca-mutated-advanced-breast-cancer 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=275&slug=imlunestrant-with-or-without-abemaciclib-in-advanced-breast-cancer 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=274&slug=randomized-phase-iii-trial-of-concurrent-accelerated-radiation-plus-cisplatin-with-or-without-cetuximab-for-stage-iii-to 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=273&slug=artscan-iii-a-randomized-phase-iii-study-comparing-chemoradiotherapy-with-cisplatin-versus-cetuximab-in-patients-with-lo 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=272&slug=radiotherapy-plus-cetuximab-or-cisplatin-in-human-papillomavirus-positive-oropharyngeal-cancer-nrg-oncology-rtog-1016-a- 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=271&slug=effect-of-hyperthermic-intraperitoneal-chemotherapy-on-cytoreductive-surgery-in-gastric-cancer-with-synchronous-peritone 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=270&slug=cytoreductive-surgery-with-or-without-hyperthermic-intraperitoneal-chemotherapy-for-gastric-cancer-with-peritoneal-metas 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=269&slug=gastrectomy-plus-chemotherapy-versus-chemotherapy-alone-for-advanced-gastric-cancer-with-a-single-non-curable-factor-reg 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=268&slug=prodigy-a-phase-iii-study-of-neoadjuvant-docetaxel-oxaliplatin-and-s-1-plus-surgery-and-adjuvant-s-1-versus-surgery-and- 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=267&slug=perioperative-or-postoperative-adjuvant-oxaliplatin-with-s-1-versus-adjuvant-oxaliplatin-with-capecitabine-in-patients-w 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=266&slug=nivolumab-versus-chemotherapy-in-patients-with-advanced-oesophageal-squamous-cell-carcinoma-refractory-or-intolerant-to- 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=265&slug=randomized-phase-iii-keynote-181-study-of-pembrolizumab-versus-chemotherapy-in-advanced-esophageal-cancer 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=264&slug=immunotherapy-and-targeted-therapy-for-advanced-gastroesophageal-cancer-asco-guideline-update 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=263&slug=zolbetuximab-plus-capox-in-cldn18-2-positive-gastric-or-gastroesophageal-junction-adenocarcinoma-the-randomized-phase-3- 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=262&slug=zolbetuximab-plus-mfolfox6-in-patients-with-cldn18-2-positive-her2-negative-untreated-locally-advanced-unresectable-or-m 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=261&slug=ramucirumab-plus-paclitaxel-versus-placebo-plus-paclitaxel-in-patients-with-previously-treated-advanced-gastric-or-gastr 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=260&slug=nivolumab-combination-therapy-in-advanced-esophageal-squamous-cell-carcinoma 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=259&slug=first-line-nivolumab-plus-chemotherapy-for-advanced-gastric-gastroesophageal-junction-and-esophageal-adenocarcinoma-3-ye 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=258&slug=trastuzumab-in-combination-with-chemotherapy-versus-chemotherapy-alone-for-treatment-of-her2-positive-advanced-gastric-o 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=257&slug=adjuvant-nivolumab-in-resected-esophageal-or-gastroesophageal-junction-cancer 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=256&slug=chemotherapy-versus-chemoradiotherapy-after-surgery-and-preoperative-chemotherapy-for-resectable-gastric-cancer-critics- 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=255&slug=randomized-phase-ii-study-of-pet-response-adapted-combined-modality-therapy-for-esophageal-cancer-mature-results-of-the- 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=254&slug=adjuvant-chemoradiotherapy-with-epirubicin-cisplatin-and-fluorouracil-compared-with-adjuvant-chemoradiotherapy-with-fluo 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=253&slug=a-randomized-phase-iii-trial-comparing-adjuvant-single-agent-s1-s-1-with-oxaliplatin-and-postoperative-chemoradiation-wi 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=252&slug=phase-iii-trial-to-compare-adjuvant-chemotherapy-with-capecitabine-and-cisplatin-versus-concurrent-chemoradiotherapy-in- 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=251&slug=preoperative-chemoradiotherapy-for-resectable-gastric-cancer 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=247&slug=perioperative-chemotherapy-with-fluorouracil-plus-leucovorin-oxaliplatin-and-docetaxel-versus-fluorouracil-or-capecitabi 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=246&slug=trastuzumab-deruxtecan-or-ramucirumab-plus-paclitaxel-in-gastric-cancer 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=245&slug=trastuzumab-deruxtecan-in-previously-treated-her2-positive-gastric-cancer 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=244&slug=neoadjuvant-chemoradiotherapy-followed-by-active-surveillance-versus-standard-surgery-for-oesophageal-cancer-sano-trial- 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=243&slug=randomized-study-on-dose-escalation-in-definitive-chemoradiation-for-patients-with-locally-advanced-esophageal-cancer-ar 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=242&slug=neoadjuvant-chemoradiotherapy-plus-surgery-versus-surgery-alone-for-oesophageal-or-junctional-cancer-cross-long-term-res 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=241&slug=pembrolizumab-plus-trastuzumab-and-chemotherapy-for-her2-positive-gastric-or-gastro-oesophageal-junction-adenocarcinoma- 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=240&slug=perioperative-durvalumab-in-gastric-and-gastroesophageal-junction-cancer 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=239&slug=oncological-outcomes-with-and-without-axillary-lymph-node-dissection-in-patients-with-residual-micrometastases-after-neo 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=238&slug=internal-mammary-node-irradiation-in-4541-node-positive-breast-cancer-patients-treated-with-newer-systemic-therapies-and 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=237&slug=omitting-regional-nodal-irradiation-after-response-to-neoadjuvant-chemotherapy 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=236&slug=preoperative-radiotherapy-for-retroperitoneal-sarcoma 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=235&slug=preoperative-radiotherapy-plus-surgery-versus-surgery-alone-for-patients-with-primary-retroperitoneal-sarcoma-eortc-6209 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=234&slug=neoadjuvant-radiotherapy-for-primary-retroperitoneal-well-differentiated-liposarcoma-a-transatlantic-australasian-retrop 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=232&slug=induction-vs-adjuvant-chemoradiotherapy-in-patients-with-high-risk-n2-to-n3-nasopharyngeal-carcinoma-a-phase-3-randomize 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=231&slug=metronomic-capecitabine-as-adjuvant-therapy-in-locoregionally-advanced-nasopharyngeal-carcinoma-a-multicentre-open-label 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=230&slug=chemoradiation-comparing-cisplatin-versus-carboplatin-in-locally-advanced-nasopharyngeal-cancer-randomised-non-inferiori 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=229&slug=results-of-phase-iii-randomized-trial-for-use-of-docetaxel-as-a-radiosensitizer-in-patients-with-head-and-neck-cancer-un 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=228&slug=gemcitabine-plus-cisplatin-versus-fl-uorouracil-plus-cisplatin-in-recurrent-or-metastatic-nasopharyngeal-carcinoma-a-mul 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=227&slug=chemotherapy-and-radiotherapy-in-nasopharyngeal-carcinoma-an-update-of-the-mac-npc-meta-analysis 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=226&slug=long-term-update-of-a-phase-3-randomized-study-comparing-once-a-week-versus-once-every-3-weeks-cisplatin-along-with-radi 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=225&slug=toripalimab-plus-chemotherapy-for-recurrent-or-metastatic-nasopharyngeal-carcinoma-the-jupiter-02-randomized-clinical-tr 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=224&slug=final-results-of-local-regional-control-and-late-toxicity-of-rtog-9003-a-randomized-trial-of-altered-fractionation-radia 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=223&slug=meta-analysis-of-chemotherapy-in-head-and-neck-cancer-mach-nc-an-update-on-107-randomized-trials-and-19-805-patients-on- 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=222&slug=role-of-radiotherapy-fractionation-in-head-and-neck-cancers-march-an-updated-meta-analysis 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=221&slug=hyperfractionated-or-accelerated-radiotherapy-in-head-and-neck-cancer-a-meta-analysis 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=220&slug=defining-risk-levels-in-locally-advanced-head-and-neck-cancers-a-comparative-analysis-of-concurrent-postoperative-radiat 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=219&slug=neoadjuvant-chemotherapy-for-locoregionally-advanced-squamous-cell-carcinoma-of-the-paranasal-sinuses 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=218&slug=induction-chemotherapy-response-as-a-guide-for-treatment-optimization-in-sinonasal-undifferentiated-carcinoma 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=217&slug=nivolumab-for-recurrent-squamous-cell-carcinoma-of-the-head-and-neck 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=216&slug=cetuximab-docetaxel-and-cisplatin-versus-platinum-fluorouracil-and-cetuximab-as-first-line-treatment-in-patients-with-re 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=215&slug=pembrolizumab-with-or-without-chemotherapy-in-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma-updated-resu 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=214&slug=adjuvant-cemiplimab-or-placebo-in-high-risk-cutaneous-squamous-cell-carcinoma 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=213&slug=neoadjuvant-cemiplimab-for-stage-ii-to-iv-cutaneous-squamous-cell-carcinoma 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=212&slug=neoadjuvant-adjuvant-or-adjuvant-only-pembrolizumab-in-advanced-melanoma 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=211&slug=neoadjuvant-nivolumab-and-ipilimumab-in-resectable-stage-iii-melanoma 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=210&slug=perioperative-chemotherapy-or-preoperative-chemoradiotherapy-in-esophageal-cancer 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=209&slug=induction-chemotherapy-followed-by-radiotherapy-vs-chemoradiotherapy-in-nasopharyngeal-carcinoma-a-randomized-clinical-t 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=208&slug=gemcitabine-and-cisplatin-induction-chemotherapy-in-nasopharyngeal-carcinoma 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=207&slug=zanidatamab-with-and-without-tislelizumab-in-her2-positive-gastroesophageal-cancer 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=206&slug=postoperative-irradiation-with-or-without-concomitant-chemotherapy-for-locally-advanced-head-and-neck-cancer 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=205&slug=postoperative-concurrent-radiotherapy-and-chemotherapy-for-high-risk-squamous-cell-carcinoma-of-the-head-and-neck 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=204&slug=neoadjuvant-and-adjuvant-pembrolizumab-in-locally-advanced-head-and-neck-cancer-keynote-689 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=203&slug=nivolumab-added-to-cisplatin-and-radiotherapy-versus-cisplatin-and-radiotherapy-alone-after-surgery-for-people-with-squa 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=202&slug=postoperative-radiotherapy-cetuximab-for-intermediate-risk-head-and-neck-cancer 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=201&slug=radiotherapy-plus-cetuximab-for-squamous-cell-carcinoma-of-the-head-and-neck 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=199&slug=cisplatin-and-fluorouracil-alone-or-with-docetaxel-in-head-and-neck-cancer 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=198&slug=cisplatin-fluorouracil-and-docetaxel-in-unresectable-head-and-neck-cancer 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=197&slug=induction-chemotherapy-followed-by-cisplatin-or-cetuximab-concomitant-to-radiotherapy-for-laryngeal-hypopharyngeal-cance 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=196&slug=long-term-results-of-rtog-91-11-a-comparison-of-three-nonsurgical-treatment-strategies-to-preserve-the-larynx-in-patient 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=195&slug=long-term-results-of-a-multicenter-randomized-phase-iii-trial-of-induction-chemotherapy-with-cisplatin-5-fluorouracil-do 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=194&slug=sacituzumab-govitecan-plus-pembrolizumab-for-advanced-triple-negative-breast-cancer 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=192&slug=trastuzumab-deruxtecan-plus-pertuzumab-for-her2-positive-metastatic-breast-cancer 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=191&slug=improved-outcomes-with-enzalutamide-in-biochemically-recurrent-prostate-cancer 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=190&slug=empire-1-randomized-trial-comparing-conventional-vs-conventional-plus-fluciclovine-18f-pet-ct-imaging-guided-post-prosta 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=189&slug=radiation-dose-escalation-or-longer-androgen-suppression-to-prevent-distant-progression-in-men-with-locally-advanced-pro 2026-05-29 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=188&slug=randomized-controlled-trial-of-early-zoledronic-acid-in-men-with-castration-sensitive-prostate-cancer-and-bone-metastase 2026-05-28 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=187&slug=stereotactic-ablative-radiotherapy-versus-standard-of-care-palliative-treatment-in-patients-with-oligometastatic-cancers 2026-05-28 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=184&slug=pembrolizumab-and-chemotherapy-in-high-risk-early-stage-er-her2-breast-cancer-a-randomized-phase-3-trial 2026-05-28 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=183&slug=her2climb-05-a-phase-iii-study-of-tucatinib-versus-placebo-in-combination-with-trastuzumab-and-pertuzumab-as-first-line- 2026-05-28 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=182&slug=palbociclib-for-hormone-receptor-positive-her2-positive-advanced-breast-cancer 2026-05-28 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=181&slug=trastuzumab-deruxtecan-in-previously-treated-her2-positive-breast-cancer 2026-05-28 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=180&slug=trastuzumab-deruxtecan-versus-trastuzumab-emtansine-for-breast-cancer 2026-05-28 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=179&slug=trastuzumab-emtansine-for-her2-positive-advanced-breast-cancer 2026-05-28 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=178&slug=pertuzumab-trastuzumab-and-docetaxel-in-her2-positive-metastatic-breast-cancer 2026-05-28 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=177&slug=datopotamab-deruxtecan-in-patients-with-untreated-advanced-triple-negative-breast-cancer-tropion-breast02-a-randomised-o 2026-05-26 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=175&slug=adjuvant-epirubicin-plus-cyclophosphamide-followed-by-taxanes-with-or-without-carboplatin-in-early-stage-triple-negative 2026-05-26 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=174&slug=sacituzumab-govitecan-in-metastatic-triple-negative-breast-cancer 2026-05-26 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=173&slug=talazoparib-in-patients-with-advanced-breast-cancer-and-a-germline-brca-mutation 2026-05-26 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=172&slug=trastuzumab-deruxtecan-in-previously-treated-her2-low-advanced-breast-cancer 2026-05-26 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=171&slug=pembrolizumab-plus-chemotherapy-in-advanced-triple-negative-breast-cancer 2026-05-26 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=170&slug=olaparib-for-metastatic-breast-cancer-in-patients-with-a-germline-brca-mutation 2026-05-26 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=163&slug=doxorubicin-for-favorable-histology-stage-ii-iii-wilms-tumor 2026-05-23 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=164&slug=omission-of-doxorubicin-from-the-treatment-of-stage-ii-iii-intermediate-risk-wilms-tumour-siop-wt-2001-an-open-label-non 2026-05-23 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=165&slug=outcome-of-localised-blastemal-type-wilms-tumour-patients-treated-according-to-intensified-treatment-in-the-siop-wt-2001 2026-05-23 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=166&slug=the-treatment-of-wilms-039-tumor-results-of-the-second-national-wilms-039-tumor-study 2026-05-23 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=167&slug=results-of-the-united-kingdom-children-039s-cancer-study-group-first-wilms-039-tumor-study 2026-05-23 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=168&slug=treatment-of-wilms-039-tumor-results-of-the-third-national-wilms-039-tumor-study 2026-05-23 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=169&slug=the-treatment-of-wilms-039-tumor-results-of-the-national-wilms-039-tumor-study 2026-05-23 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=159&slug=rhabdomyosarcoma-of-the-head-and-neck-a-multimodal-approach 2026-05-22 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=160&slug=orbital-rhabdomyosarcoma-a-comprehensive-review-of-clinical-features-molecular-advances-and-current-management 2026-05-22 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=161&slug=current-and-future-developments-in-radiation-oncology-approach-for-rhabdomyosarcoma 2026-05-22 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=162&slug=orbital-rhabdomyosarcoma-comprehensive-review-of-epidemiology-clinical-staging-and-treatment-outcomes 2026-05-22 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=158&slug=continued-treatment-effect-of-zoledronic-acid-dosing-every-12-vs-4-weeks-in-women-with-breast-cancer-metastatic-to-bone- 2026-05-06 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=157&slug=efficacy-of-chemotherapy-for-er-negative-and-er-positive-isolated-locoregional-recurrence-of-breast-cancer-final-analysi 2026-05-06 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=153&slug=atac-arimidex-tamoxifen-alone-or-in-combination-trial 2026-05-06 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=154&slug=results-of-the-atac-arimidex-tamoxifen-alone-or-in-combination-trial-after-completion-of-5-years-adjuvant-treatment-for- 2026-05-06 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=155&slug=adjuvant-exemestane-with-ovarian-suppression-in-premenopausal-breast-cancer-long-term-follow-up-of-the-combined-text-and 2026-05-06 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=156&slug=long-term-effects-of-continuing-adjuvant-tamoxifen-to-10-years-versus-stopping-at-5-years-after-diagnosis-of-oestrogen-r 2026-05-06 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=152&slug=adjuvant-ribociclib-plus-nonsteroidal-aromatase-inhibitor-therapy-in-patients-with-hr-positive-her2-negative-early-breas 2026-05-06 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=147&slug=chemotherapy-ct-and-hormonotherapy-ht-as-neoadjuvant-treatment-in-luminal-breast-cancer-patients-results-from-the-geicam 2026-05-06 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=148&slug=neo-adjuvant-chemotherapy-in-luminal-node-positive-breast-cancer-characteristics-treatment-and-oncological-outcomes-a-si 2026-05-06 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=149&slug=neoadjuvant-chemotherapy-for-luminal-a-breast-cancer-factors-predictive-of-histopathologic-response-and-oncologic-outcom 2026-05-06 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=150&slug=is-adjuvant-chemotherapy-necessary-for-luminal-a-like-breast-cancer 2026-05-06 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=144&slug=randomized-phase-ii-trial-of-endocrine-therapy-with-or-without-ribociclib-after-progression-on-cyclin-dependent-kinase-4 2026-05-06 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=145&slug=final-results-of-right-choice-ribociclib-plus-endocrine-therapy-versus-combination-chemotherapy-in-premenopausal-women-w 2026-05-06 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=146&slug=phase-i-ii-trial-of-triplet-therapy-exemestane-ribociclib-and-everolimus-after-progression-on-a-cdk4-6-inhibitor-in-hr-h 2026-05-06 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=134&slug=overall-survival-with-ribociclib-plus-endocrine-therapy-in-breast-cancer 2026-05-06 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=135&slug=palbociclib-and-letrozole-in-advanced-breast-cancer 2026-05-06 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=136&slug=updated-results-from-monaleesa-2-a-phase-iii-trial-of-first-line-ribociclib-plus-letrozole-versus-placebo-plus-letrozole 2026-05-06 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=137&slug=overall-survival-results-from-the-randomized-phase-2-study-of-palbociclib-in-combination-with-letrozole-versus-letrozole 2026-05-06 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=138&slug=paloma-3-phase-iii-trial-of-fulvestrant-with-or-without-palbociclib-in-premenopausal-and-postmenopausal-women-with-hormo 2026-05-06 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=139&slug=abemaciclib-combined-with-endocrine-therapy-for-the-adjuvant-treatment-of-hr-her2-node-positive-high-risk-early-breast-c 2026-05-06 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=140&slug=monarch-2-abemaciclib-in-combination-with-fulvestrant-in-women-with-hr-her2-advanced-breast-cancer-who-had-progressed-wh 2026-05-06 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=141&slug=monarch-3-abemaciclib-as-initial-therapy-for-advanced-breast-cancer 2026-05-06 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=142&slug=updated-overall-survival-from-the-monaleesa-3-trial-in-postmenopausal-women-with-hr-her2-advanced-breast-cancer-receivin 2026-05-06 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=143&slug=efficacy-safety-and-patient-reported-outcomes-across-young-to-older-age-groups-of-patients-with-hr-her2-advanced-breast- 2026-05-06 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=133&slug=monarch-1-a-phase-2-study-of-abemaciclib-a-cdk4-and-cdk6-inhibitor-as-a-single-agent-in-patients-with-refractory-hr-her2 2026-05-06 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=132&slug=abemaciclib-plus-fulvestrant-in-advanced-breast-cancer-after-progression-on-cdk4-6-inhibition-results-from-the-phase-iii 2026-05-06 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=130&slug=intermediate-risk-meningioma-initial-outcomes-from-nrg-oncology-rtog-0539 2026-02-26 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=129&slug=trimodality-therapy-versus-perioperative-chemotherapy-in-the-management-of-locally-advanced-adenocarcinoma-of-the-oesoph 2026-02-26 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=128&slug=sentinel-node-biopsy-after-neoadjuvant-chemotherapy-in-biopsy-proven-node-positive-breast-cancer-the-sn-fnac-study 2026-02-26 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=127&slug=overall-survival-in-the-olympia-phase-iii-trial-of-adjuvant-olaparib-in-patients-with-germline-pathogenic-variants-in-br 2026-02-26 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=125&slug=adjuvant-capecitabine-for-breast-cancer-after-preoperative-chemotherapy 2026-02-26 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=124&slug=adjuvant-palbociclib-for-early-breast-cancer-the-pallas-trial-results-abcsg-42-aft-05-big-14-03 2026-02-26 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=123&slug=single-modality-endocrine-therapy-versus-radiotherapy-after-breast-conserving-surgery-in-women-aged-70-years-and-older-w 2026-02-24 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=122&slug=breast-conserving-surgery-with-or-without-irradiation-in-early-breast-cancer 2026-02-24 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=121&slug=postoperative-radiotherapy-omission-in-ed-patients-with-early-breast-cancer-following-preoperative-breast-mri-prospect-p 2026-02-24 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=120&slug=regional-nodal-irradiation-in-early-stage-breast-cancer 2026-02-24 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=119&slug=adjuvant-durvalumab-in-completely-resected-early-stage-non-small-cell-lung-cancer 2026-02-24 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=118&slug=hypofractionated-stereotactic-radiotherapy-versus-whole-brain-radiotherapy-following-brain-metastasis-resection-results- 2026-02-24 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=117&slug=neoadjuvant-trastuzumab-deruxtecan-alone-or-followed-by-paclitaxel-trastuzumab-and-pertuzumab-for-high-risk-her2-positiv 2026-02-23 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=116&slug=extended-endocrine-therapy-following-5-years-of-adjuvant-luteinizing-hormone-releasing-hormone-agonist-in-premenopausal- 2026-02-23 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=114&slug=prophylactic-cranial-irradiation-versus-observation-in-patients-with-extensive-disease-small-cell-lung-cancer-a-multicen 2026-02-23 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=113&slug=efficacy-and-safety-of-neoadjuvant-pertuzumab-and-trastuzumab-in-women-with-locally-advanced-inflammatory-or-early-her2- 2026-02-23 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=112&slug=adjuvant-endocrine-therapy-in-premenopausal-breast-cancer-12-year-results-from-soft 2026-02-23 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=111&slug=long-term-efficacy-analysis-of-the-randomised-phase-ii-tryphaena-cardiac-safety-study-evaluating-pertuzumab-and-trastuzu 2026-02-23 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=110&slug=the-uk-standardisation-of-breast-radiotherapy-start-trial-b-of-radiotherapy-hypofractionation-for-treatment-of-early-bre 2026-02-23 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=106&slug=alectinib-in-resected-alk-positive-non-small-cell-lung-cancer 2026-02-22 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=107&slug=overall-survival-with-osimertinib-in-resected-egfr-mutated-nsclc 2026-02-22 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=108&slug=adjuvant-atezolizumab-after-adjuvant-chemotherapy-in-resected-stage-ib-iiia-non-small-cell-lung-cancer-impower010-a-rand 2026-02-22 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=109&slug=pembrolizumab-versus-placebo-as-adjuvant-therapy-for-completely-resected-stage-ib-iiia-non-small-cell-lung-cancer-pearls 2026-02-22 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=104&slug=durvalumab-after-chemoradiotherapy-in-stage-iii-non-small-cell-lung-cancer 2026-02-22 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=105&slug=long-term-results-of-nrg-oncology-rtog-0617-standard-versus-high-dose-chemoradiotherapy-with-or-without-cetuximab-for-un 2026-02-22 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=103&slug=overall-survival-with-neoadjuvant-nivolumab-plus-chemotherapy-in-lung-cancer 2026-02-22 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=91&slug=paclitaxel-carboplatin-alone-or-with-bevacizumab-for-non-small-cell-lung-cancer 2026-02-22 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=92&slug=overall-survival-with-osimertinib-in-untreated-egfr-mutated-advanced-nsclc 2026-02-22 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=93&slug=alectinib-versus-crizotinib-in-untreated-alk-positive-non-small-cell-lung-cancer 2026-02-22 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=94&slug=five-year-survival-outcomes-with-nivolumab-plus-ipilimumab-versus-chemotherapy-as-first-line-treatment-for-metastatic-no 2026-02-22 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=95&slug=pembrolizumab-plus-chemotherapy-in-squamous-non-small-cell-lung-cancer-5-year-update-of-the-phase-iii-keynote-407-study 2026-02-22 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=96&slug=atezolizumab-for-first-line-treatment-of-metastatic-nonsquamous-nsclc 2026-02-22 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=97&slug=pemetrexed-bevacizumab-or-the-combination-as-maintenance-therapy-for-advanced-nonsquamous-non-small-cell-lung-cancer-eco 2026-02-22 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=98&slug=updated-analysis-of-keynote-024-pembrolizumab-versus-platinum-based-chemotherapy-for-advanced-non-small-cell-lung-cancer 2026-02-22 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=99&slug=pembrolizumab-versus-chemotherapy-for-previously-untreated-pd-l1-expressing-locally-advanced-or-metastatic-non-small-cel 2026-02-22 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=100&slug=updated-overall-survival-analysis-from-impower110-atezolizumab-versus-platinum-based-chemotherapy-in-treatment-naive-pro 2026-02-22 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=101&slug=patient-reported-outcomes-following-pembrolizumab-or-placebo-plus-pemetrexed-and-platinum-in-patients-with-previously-un 2026-02-22 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=102&slug=first-line-nivolumab-plus-ipilimumab-combined-with-two-cycles-of-chemotherapy-in-patients-with-non-small-cell-lung-cance 2026-02-22 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=90&slug=interrupting-endocrine-therapy-to-attempt-pregnancy-after-breast-cancer 2026-02-22 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=89&slug=zoledronic-acid-zoledronate-for-postmenopausal-women-with-early-breast-cancer-receiving-adjuvant-letrozole-zo-fast-study 2026-02-22 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=87&slug=trastuzumab-deruxtecan-in-residual-her2-positive-early-breast-cancer 2026-02-22 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=86&slug=trastuzumab-emtansine-for-residual-invasive-her2-positive-breast-cancer 2026-02-22 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=85&slug=adjuvant-pertuzumab-and-trastuzumab-in-early-her2-positive-breast-cancer 2026-02-22 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=84&slug=perioperative-chemotherapy-versus-surgery-alone-for-resectable-gastroesophageal-cancer 2026-02-22 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=83&slug=long-term-results-of-rtog-trial-8911-usa-intergroup-113-a-random-assignment-trial-comparison-of-chemotherapy-followed-by 2026-02-22 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=82&slug=updated-analysis-of-swog-directed-intergroup-study-0116-a-phase-iii-trial-of-adjuvant-radiochemotherapy-versus-observati 2026-02-22 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=81&slug=treatment-for-brain-metastases-with-stereotactic-radiation-vs-hippocampal-avoidance-whole-brain-radiation-a-randomized-c 2026-02-21 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=76&slug=effect-of-nivolumab-vs-bevacizumab-in-patients-with-recurrent-glioblastoma-the-checkmate-143-phase-3-randomized-clinical 2026-02-21 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=77&slug=bevacizumab-plus-irinotecan-versus-temozolomide-in-newly-diagnosed-o6-methylguanine-dna-methyltransferase-nonmethylated- 2026-02-21 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=78&slug=regorafenib-compared-with-lomustine-in-patients-with-relapsed-glioblastoma-regoma-a-multicentre-open-label-randomised-co 2026-02-21 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=79&slug=phase-2-study-of-concurrent-radiotherapy-and-temozolomide-followed-by-temozolomide-and-lomustine-in-the-treatment-of-chi 2026-02-21 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=80&slug=bevacizumab-plus-irinotecan-in-recurrent-glioblastoma-multiforme 2026-02-21 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=62&slug=randomized-phase-ii-iii-trial-of-veliparib-or-placebo-in-combination-with-adjuvant-temozolomide-in-newly-diagnosed-gliob 2026-02-21 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=63&slug=rtog-0211-a-phase-i-ii-study-of-radiation-therapy-with-concurrent-gefitinib-for-newly-diagnosed-glioblastoma-patients 2026-02-21 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=64&slug=effects-of-radiotherapy-with-concomitant-and-adjuvant-temozolomide-versus-radiotherapy-alone-on-survival-in-glioblastoma 2026-02-21 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=67&slug=temozolomide-in-elderly-patients-with-newly-diagnosed-glioblastoma-and-poor-performance-status-an-anocef-phase-ii-trial 2026-02-21 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=68&slug=intellance-2-eortc-1410-randomized-phase-ii-study-of-depatux-m-alone-and-with-temozolomide-vs-temozolomide-or-lomustine- 2026-02-21 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=69&slug=phase-iii-trial-of-chemoradiotherapy-for-anaplastic-oligodendroglioma-long-term-results-of-rtog-9402 2026-02-21 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=70&slug=temozolomide-chemotherapy-alone-versus-radiotherapy-alone-for-malignant-astrocytoma-in-the-elderly-the-noa-08-randomised 2026-02-21 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=72&slug=nrg-oncology-rtog1205-a-randomized-phase-ii-trial-of-concurrent-bevacizumab-and-reirradiation-versus-bevacizumab-alone-a 2026-02-21 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=74&slug=safety-and-efficacy-of-bevacizumab-with-hypofractionated-stereotactic-irradiation-for-recurrent-malignant-gliomas 2026-02-21 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=61&slug=chemoradiation-atezolizumab-in-limited-stage-small-cell-lung-cancer-results-of-nrg-oncology-alliance-lu005 2026-02-20 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=60&slug=high-dose-once-daily-thoracic-radiotherapy-in-limited-stage-small-cell-lung-cancer-calgb-30610-alliance-rtog-0538 2026-02-20 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=59&slug=twice-daily-compared-with-once-daily-thoracic-radiotherapy-in-limited-small-cell-lung-cancer-treated-concurrently-with-c 2026-02-20 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=58&slug=first-line-atezolizumab-plus-chemotherapy-in-extensive-stage-small-cell-lung-cancer 2026-02-20 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=57&slug=durvalumab-with-or-without-tremelimumab-plus-platinum-etoposide-in-first-line-treatment-of-extensive-stage-small-cell-lu 2026-02-20 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=55&slug=a-phase-iii-trial-of-adjuvant-ribociclib-plus-endocrine-therapy-versus-endocrine-therapy-alone-in-patients-with-hr-posit 2026-02-19 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=54&slug=adjuvant-olaparib-for-patients-with-brca1-or-brca2-mutated-breast-cancer 2026-02-19 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=53&slug=adjuvant-chemotherapy-guided-by-a-21-gene-expression-assay-in-breast-cancer 2026-02-19 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=52&slug=21-gene-assay-to-inform-chemotherapy-benefit-in-node-positive-breast-cancer 2026-02-19 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=51&slug=the-nsabp-study-of-tamoxifen-and-raloxifene-star-trial 2026-02-19 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=49&slug=partial-breast-radiotherapy-after-breast-conservation-surgery-for-patients-with-early-breast-cancer-uk-import-low-trial- 2026-02-19 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=48&slug=radiotherapy-or-surgery-of-the-axilla-after-a-positive-sentinel-node-in-breast-cancer-eortc-10981-22023-amaros-a-randomi 2026-02-19 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=46&slug=watch-and-wait-approach-versus-surgical-resection-after-chemoradiotherapy-for-patients-with-rectal-cancer-the-oncore-pro 2026-02-18 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=45&slug=preoperative-radiotherapy-combined-with-total-mesorectal-excision-for-resectable-rectal-cancer-12-year-follow-up-of-the- 2026-02-18 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=44&slug=improved-survival-with-preoperative-radiotherapy-in-resectable-rectal-cancer 2026-02-18 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=43&slug=preoperative-versus-postoperative-chemoradiotherapy-for-rectal-cancer 2026-02-18 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=41&slug=sentinel-lymph-node-resection-compared-with-conventional-axillary-lymph-node-dissection-in-clinically-node-negative-pati 2026-02-18 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=42&slug=axillary-dissection-vs-no-axillary-dissection-in-women-with-invasive-breast-cancer-and-sentinel-node-metastasis 2026-02-18 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=37&slug=axillary-dissection-versus-no-axillary-dissection-in-patients-with-sentinel-node-micrometastases-ibcsg-23-01-a-phase-3-r 2026-02-18 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=38&slug=determinants-of-diagnostic-performance-of-f-18-fluorodeoxyglucose-positron-emission-tomography-for-axillary-staging-in-b 2026-02-18 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=39&slug=sentinel-lymph-node-biopsy-vs-no-axillary-surgery-in-patients-with-small-breast-cancer-and-negative-results-on-ultrasono 2026-02-18 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=40&slug=axillary-surgery-in-breast-cancer-primary-results-of-the-insema-trial 2026-02-18 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=30&slug=randomized-phase-iii-trial-evaluating-radiation-following-surgical-excision-for-good-risk-ductal-carcinoma-in-situ-long- 2026-02-18 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=31&slug=adjuvant-tamoxifen-reduces-subsequent-breast-cancer-in-women-with-estrogen-receptor-positive-ductal-carcinoma-in-situ-a- 2026-02-18 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=32&slug=association-of-radiotherapy-with-survival-in-women-treated-for-ductal-carcinoma-in-situ-with-lumpectomy-or-mastectomy 2026-02-18 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=33&slug=the-comet-comparison-of-operative-versus-monitoring-and-endocrine-therapy-trial-a-phase-iii-randomised-controlled-clinic 2026-02-18 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=34&slug=overview-of-the-randomized-trials-of-radiotherapy-in-ductal-carcinoma-in-situ-of-the-breast 2026-02-18 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=35&slug=pathologic-findings-from-the-national-surgical-adjuvant-breast-project-nsabp-protocol-b-17 2026-02-18 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=27&slug=ivosidenib-for-the-treatment-of-idh1-mutant-glioma-grades-2-4-tolerability-predictors-of-response-and-outcomes 2026-02-16 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=26&slug=darolutamide-plus-androgen-deprivation-therapy-and-docetaxel-in-metastatic-hormone-sensitive-prostate-cancer-by-disease- 2026-02-15 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=25&slug=niraparib-and-abiraterone-acetate-plus-prednisolone-for-hrr-deficient-metastatic-castration-sensitive-prostate-cancer-a- 2026-02-15 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=23&slug=177lu-prostate-specific-membrane-antigen-neoadjuvant-to-stereotactic-ablative-radiotherapy-for-oligorecurrent-prostate-c 2026-02-15 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=22&slug=nivolumab-plus-docetaxel-versus-placebo-plus-docetaxel-for-androgen-receptor-pathway-inhibitor-pretreated-and-chemothera 2026-02-15 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=21&slug=ascende-rt-an-analysis-of-treatment-related-morbidity-for-a-randomized-trial-comparing-a-low-dose-rate-brachytherapy-boo 2026-02-15 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=20&slug=apalutamide-in-patients-with-metastatic-castration-sensitive-prostate-cancer-final-survival-analysis-of-the-randomized-d 2026-02-14 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=19&slug=radiotherapy-to-the-primary-tumour-for-newly-diagnosed-metastatic-prostate-cancer-stampede-a-randomised-controlled-phase 2026-02-14 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=18&slug=abiraterone-acetate-plus-prednisolone-in-patients-with-newly-diagnosed-high-risk-metastatic-castration-sensitive-prostat 2026-02-14 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=17&slug=enzalutamide-with-standard-first-line-therapy-in-metastatic-prostate-cancer 2026-02-14 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=16&slug=chemohormonal-therapy-in-metastatic-hormone-sensitive-prostate-cancer-long-term-survival-analysis-of-the-randomized-phas 2026-02-14 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=15&slug=arches-a-randomized-phase-iii-study-of-androgen-deprivation-therapy-with-enzalutamide-or-placebo-in-men-with-metastatic- 2026-02-14 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=14&slug=adjuvant-temozolomide-chemotherapy-with-or-without-interferon-alfa-among-patients-with-newly-diagnosed-high-grade-glioma 2026-02-14 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=13&slug=randomized-comparison-of-stereotactic-radiosurgery-followed-by-conventional-radiotherapy-with-carmustine-to-conventional 2026-02-14 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=9&slug=a-randomized-trial-of-bevacizumab-for-newly-diagnosed-glioblastoma 2026-02-14 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=8&slug=phase-iii-randomized-study-of-radiation-and-temozolomide-versus-radiation-and-nitrosourea-therapy-for-anaplastic-astrocy 2026-02-14 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=7&slug=phase-ii-trial-of-pre-irradiation-and-concurrent-temozolomide-in-patients-with-newly-diagnosed-anaplastic-oligodendrogli 2026-02-14 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=5&slug=adjuvant-procarbazine-lomustine-and-vincristine-chemotherapy-in-newly-diagnosed-anaplastic-oligodendroglioma-long-term-f 2026-02-14 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=4&slug=noa-04-randomized-phase-iii-trial-of-sequential-radiochemotherapy-of-anaplastic-glioma-with-procarbazine-lomustine-and-v 2026-02-14 weekly 0.8 https://oncomarks.com/Trial_View.php?Study_ID=3&slug=timing-of-radiotherapy-after-radical-prostatectomy-radicals-rt-a-randomised-controlled-phase-3-trial 2026-02-14 weekly 0.8